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CHAPTER 1 
INTRODUCTION 

Allogeneic bone marrow transplantat ion has evolved from an 
experimental treatment to a worldwide accepted method to treat a 
n u m b e r of severe disorders like leukemia, myelodysplastic 
syndrome, bone marrow failure, immune deficiency, storage 
diseases, and hemoglobinopathies.1 This evolution is described in 
chapter 2 of this thesis. Worldwide, more than 40,000 patients 
have received a bone marrow graft from a donor. In 1993 the 250th 
allogeneic bone marrow transplantation will be performed at the 
Bone Marrow Transplantation Unit of the University Hospital 
Nijmegen. Results of the first eighty consecutive pat ients 
t ransplanted in this center for acute leukemia and chronic 
myelogenous leukemia are given in chapter 3. Special emphasis is 
put on chimerism and chimerism is the main theme of the present 
thesis. 
The term chimera refers to a monster in greek mythology. This 
monster, the "Chimera", resembled a lion in the forepart, a goat in 
the middle and a dragon behind. 2 · 3 She terrorized Asia Minor and 
was ultimately killed by Bellerophon, hero of C o r i n t h . 4 · 5 In the 
scientific literature, chimerism has been defined as an organism 
whose cells have been derived from two or more distinct zygotic 
l i n e a g e s . 6 In bone marrow transplantation, a chimera is the 
recipient of a successfully engrafted marrow. Although the term 
chimera refers to an organism and not to a tissue, the term 
chimera h a s been more specifically defined on the base of the 
origin of the lympho-hematopoietic cells. If all lympho-
hematopoietlc cells are of donor origin, the chimera Is a complete 
donor chimera and the recipient has a complete donor chimera. If 
one or more lympho-hematopoietic cell lineages in the blood 
and/or the bone marrow are of recipient origin and one or more 
other cell lineages гиге of donor origin, the chimera is a mixed 
chimera and the recipient h a s a mixed chimera (or Incomplete 
chimera). However, the term Incomplete chimera is confusing 
since it suggests incomplete In the sense of inadequate 
hematopoiesis. 
Mixed chimeras are more frequent in recipients of Τ cell 
depleted grafts than in patients transplanted with unmanlpulated 
bone m a r r o w . 7 - 1 1 Persistence or endogenous repopulation of host-
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type lympho-hematopoietic cells after allogeneic transplantation for 
leukemia have been considered a poor prognostic sign, indicating 
manifest or imminent r e l a p s e . 1 2 ' 1 4 In chapter 4 we show that 
mixed hematopoietic chimerism after allogeneic transplantation 
with lymphocyte depleted grafts using counterflow centrifugation, 
is not associated with a higher incidence of relapse. Furthermore, 
we demonstrate that chimerism may differ between the various 
subsets of cells analyzed. A comparison of chimerism of red cells, 
granulocytes, Τ lymphocytes, and bone marrow cells is made in 
chapter 5 and results of cytogenetic analysis of lymphocytes and 
bone marrow cells are given in chapter 6. 
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CHAPTER 2 
HISTORICAL OVERVIEW ON 
BONE MARROW TRANSPLANTATION 

THE FIRST HISTORICAL ATTEMPTS AT BONE MARROW 
TRANSPLANTATION 
One of the first observations on bone marrow transplantation was 
made by Neuhof In 1923. He observed that marrow transplanted 
along with autologous* bone degenerated in the first week and was 
replaced by hematopoietic cells which were probably not derived 
from persisting portions of the original graft bu t from adjacent 
marrow. In 1930, Loeb briefly referred to necrosis of bone marrow 
and rep lacemen t by fibrous t i s sue after s i m u l t a n e o u s 
transplantation with autologous, allogeneic, or xenogeneic bone.2 
In 1937, a 19-year-old woman suffering from aplastic anemia was 
treated by Osgood and colleagues.3 She was given pentose 
nucleotide, liver extract, and 43 units of blood within a period of 52 
days. Ultimately, "when all hope from other methods of therapy 
seemed gone" she received Intravenously 18 ml of sternal marrow 
together with 575 ml blood from her blood group-identical brother. 
Five days later she died. At necropsy occasional islets of 
regenerating marrow were found and the authors did not exclude 
that these had been derived from the Injected marrow cells. 
Morrison and Samwick wondered if an unknown maturing factor 
present in normal bone marrow lacked In aplastic anemia and 
leukemia analogous to the Intrinsic factor as the erythrocyte 
maturing factor in pernicious anemia.4 In 1940 they treated a 42-
year-old man suffering from idiopathic aplastic anemia with pentose 
nucleotide, liver extract and transfusions of whole blood followed by 
intrastemal injection of bone marrow. A total dose of 8 ml, which 
was obtained from the patient 's brother, was given on two 
consecutive days. On the third day, 5 ml bone marrow from another 
•In this overview autologous refers to transplantation within the same Individual. 
Syngeneic (Isologous) refers to transplantation within an Inbred strain or between 
Identical twins (genotyplcally Identical Individuals). Allogeneic (homologous) 
refers to transplantation between Inbred strains or between not genotyplcally 
Identical Individuals of the same species. Xenogeneic (heterologous) refers to 
transplantation between different species. 
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donor was Injected Intrastemally. Within two days after the last 
Injection, platelets began to rise followed by an increase in white 
and red blood cells and normalization of differential counts, and a 
marked increase of hematopoietic elements in the bone marrow. 
The patient recovered and the authors concluded that a unknown 
factor present in normal bone marrow, might have stimulated 
maturation of hematopoietic constituents already present in the 
diseased marrow. 
In 1950, Rekers et al reported on transplantation of allogeneic 
bone marrow in dogs after exposure to 350 röntgen* of body 
irradiation.5 The bone marrow suspension had been administered 
intramedullary, intravenously, in the spleen or in the liver. 
However, all transplants failed to grow. Jacobson et cd showed that 
mice exposed to a lethal dosis of total body irradiation of 1,025 
röntgen did not suffer from anemia and had only a transient leuko-
and thrombocytopenia if the surgically mobilized spleen had been 
covered by lead during irradiation.6·7 Immediate extirpation of the 
shielded spleen within 5 minutes after irradiation caused death in 
all mice but postponed extirpation of the shielded spleen 1 to 6 
hours after irradiation had no deleterious effect on recovery. From 
these experiments the authors concluded tha t a non-cellular 
substance produced by the shielded spleen was responsible for 
recovery from radiation injury. This has been questioned by Lorenz 
et al who believed that not a humoral but a cellular factor was 
responsible for survival.8 They Injected mice intravenously or 
intraperitoneally with syngeneic marrow after irradiation with 900 
röntgen. Twenty-eight out of 37 (76%) mice were alive at 28 days 
compared to none of 28 irradiated animals which had not received 
bone marrow. Active areas of hematopoietic tissue were found in 
mice infused with bone marrow but not the control animals. 
However, their experiments did not exclude a humoral factor. 
Lindsley and colleagues t ransplanted ra t s with allogeneic 
marrow. 9 In rats irradiated with doses in the LD50 range, donor-
type red blood cells were found after 2 to 3 weeks but not in rats 
which were not irradiated. Using mice with a specific marker-
•for clinical purposes, one röntgen may be read as one rem, one rad. or one cGy. 
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chromosome as bone marrow donor for mice without this marker, 
Ford et al demonstrated dividing cells of donor origin in the bone 
marrow, the spleen, the lymph nodes, and the thymus of mice after 
irradiation and intravenous injection of donor spleen suspension.1 0 
Virtually all host bone marrow had been replaced by cells 
originating from the donor. In another experiment they found only 
rat chromosomes in the bone marrow of mice after irradiation and 
injection with a suspension of rat bone marrow cells. They 
concluded that Infusion of spleen suspension or bone marrow cells 
exerted Its therapeutic effect by a cellular mechanism although they 
could not exclude the possibility of simultaneous activity of a 
humoral factor. 
After it became evident that hematopoietic t issue could be 
transferred from one animal to another, but only after pretreatment 
with sufficient irradiation, possibilities had been created for the 
treatment of leukemia. In their experiments on mice in 1957, 
Barnes et al showed that a lethal dose of whole body Irradiation 
followed by transplantation of a syngeneic graft could not eradicate 
all leukemic ce l l s . 1 1 · 1 2 Mice given syngeneic marrow grafts died 
from relapsed leukemia. However, recipients of an allogeneic graft 
died from an unknown secondary syndrome with wasting bu t 
without signs of leukemia. 
In the same year, Thomas and colleagues published on 
Intravenous infusion of bone marrow in six human beings.1 3 Donor 
marrow was obtained from the long bones and ribs of fetal and adult 
cadavers, or from living donors by aspiration from the ileum or 
from ribs removed at surgery. Three patients suffered from end-
stage hematologic malignancies, two had metastatic carcinomas and 
one patient was In coma from a massive cerebral hemorrhage. The 
patients with hematologic malignancies were irradiated with doses 
varying from 300 röntgen given in three days to 600 röntgen 
divided over 17 days. The recipients with carcinoma were not 
pretreated with irradiation but were conditioned with cytostatics. 
The patient with cerebral hemorrhage was not pretreated at all. 
The total amount of nucleated bone marrow cells infused varied 
from 0.6 χ 10 9 to 3.2 χ IO 9 cells. One of the patients treated for 
carcinoma received bone marrow from two different donors. The 
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marrow was administered intravenously in one dose or in divided 
doses at different time intervals. Using differences in blood group 
antigens a very transient production of red cells of donor origin was 
suggested in two patients. None of the patients had prolonged or 
permanent engraftment. 
In 1958, Mathé et al transplanted five men who had been 
accidentally exposed to radiation emitted by a nuclear power plant 
in Belgrade.1 4 Estimated radiation exposition varied from 600 to 
1,200 rem. Twenty-seven to 36 days after the exposure the victims 
received 8.5 to 14 χ ΙΟ 9 nucleated bone marrow cells from 
unrelated donors. One patient died, the others recovered. Based on 
their studies on blood group antigens the authors postulated that 
donor marrow grafts had functioned temporarily until autologous 
bone marrow recovery. 
Ferrebee et al claimed that success of grafting depended on 
severed factors. 1 5 The recipient had to be in general good condition 
before and after irradiation, the donor marrow had to be genetically 
related and the amount of nucleated bone marrow cells infused 
should be considerable. The host immune system had to be 
impaired further by splenectomy, by the use of adreno­
corticotropic hormone (ACTH) and by irradiation. Furthermore, the 
total dose of body irradiation had to be increased or given during a 
prolonged period. A male and a female splenectomised healthy dog 
were irradiated with 100 röntgen four times dally for 3 consecutive 
days. Antibiotics and ACTH were started on the first day of 
Irradiation. Immediately after the radiation the female dog was 
given 2 χ 10 9 nucleated marrow cells from an unrelated male. 
White blood cells did not rise and this dog died from sepsis on the 
12th day. The male dog received 8.6 χ IO 9 nucleated bone marrow 
cells from a female sibling. Blood counts normalized at 14 days 
posttransplant and leukocytes showed female forms. ACTH and 
antibiotics were discontinued. Thereupon the dog developed fever, 
was "critically ill" and his blood counts dropped. Within a few days 
after restarting ACTH and antibiotics he recovered completely and 
mature granulocytes of female type reappeared. 
Congdon and Urso observed that the 15-day mortality of mice 
irradiated with 900 rontgen and transplanted with allogeneic 
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marrow was comparable with that of syngeneic grafts.16 Death was 
due to the Irradiation syndrome. A large number of mice injected 
with allogeneic marrow died during further follow-up and this was 
caused by a secondary disease process. This process (secondary 
phenomenon, secondary phase, homologous disease, delayed 
foreign bone marrow reaction, graft-versus-host reaction or graft-
versus-host disease) consisted of emaciation, dermatitis, laesions in 
the liver and gastrointestinal tract, and atrophy of lymphatic 
tissues. It was caused by a reaction of the marrow graft against the 
host. Uphoff demonstrated that the graft-versus-host reaction could 
be prevented by using fetal hematopoietic donor t issue.1 7 Following 
800 röntgen total body X irradiation F i hybrids receiving parental 
marrow died with severe diarrhea and extreme emaciation bu t 
those given parental-strain fetal hematopoietic tissue did well and 
were indistinguishable from those receiving syngeneic marrow. 
In 1960 Haurani et αϊ reported on bone marrow transplantation 
in patients with acute leukemia. 1 8 Donor marrow was obtained from 
ribs resected from unrelated donors. No more than two ribs were 
resected from a single donor. Three patients in hematological 
remission at the time of transplantation were pretreated with 50 to 
325 röntgen of irradiation and received corticosteroids in an 
attempt to impair the host immune mechanism. The number of 
nucleated cells Infused ranged from 5.4 χ IO 9 to 7.4 χ IO 9 . None of 
the three recipients showed evidence of engraftment. They 
survived for 7 to 10 months with relapsed leukemia. Six other 
patients with overt leukemia were treated with 300 to 350 röntgen 
and Infusion of 4.3 χ IO 9 to 8.6 χ ΙΟ 9 bone marrow cells. No 
evidence of engraftment was found. Five patients died within two 
months. Cause of death was infection or hemorrhage in four and 
leukemia in one recipient. The sixth patient died from leukemia at 
8 months after transplantation. 
BONE MARROW TRANSPLANTATION WITH IDENTICAL TWINS 
AND GENETICALLY UNSELECTED DONORS 
In 1959 Thomas and colleagues described two patients with acute 
leukemia who received a graft from their identical twins . 1 9 A two-
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year-old girl without signs of remission after treatment with 
cytostatics and prednisone was given 200 röntgen of total body 
Irradiation followed by 1.3 χ IO 9 nucleated donor bone marrow 
cells. Blood cell counts normalized quickly, and a bone marrow 
study performed 25 days after Irradiation showed complete 
remission. She relapsed about two months later. Within one month 
she was retransplanted with 2.3 χ IO 9 nucleated bone marrow cells 
from the same donor after irradiation with 1,140 röntgen. White 
blood cell counts rose and the bone marrow showed a normal 
maturation In myeloid and eiythrold cells without any evidence of 
leukemia. Megakaryocytes were not found, and because of failure of 
the platelet count to recover, she was given another 0.9 χ IO 9 
nucleated bone marrow cells from the same donor. A repeated bone 
marrow aspiration 48 days after irradiation showed relapse of 
leukemia. Their second patient was a 4-year-old girl with relapsed 
acute leukemia. She was pretreated with 850 röntgen of total body 
irradiation followed by the Infusion of 3.9 χ IO 9 nucleated marrow 
cells. At 13 days after Irradiation the bone marrow was normal but 
10 weeks later she relapsed. The authors concluded that leukemia 
could not be eliminated by whole body irradiation followed by 
infusion of syngeneic marrow and suggested two alternative 
approaches. Firstly, after lethal total body irradiation allogeneic 
marrow could eradicate leukemia by a n immunologic reaction. 
However, patients might die from delayed foreign marrow disease. 
Their second approach was based on observations in ¿mimais which 
showed that the possibility of cure from leukemia was greater when 
the number of leukemic cells was smaller.20 They suggested that a 
patient with a relatively small mass of leukemic cells after 
treatment with cytostatics might benefit more from irradiation and 
subsequent infusion of bone marrow cells. 
In 1961 Thomas and colleagues described bone marrow 
transplantation In five patients.2 1 Indications for transplantation 
were untreated, relapsed or resistant acute leukemias. The patients 
were nursed in isolated rooms. Dose of Irradiation varied from 
1,460 to 2,016 rontgen and was given continuously at a dose-rate of 
0.5 to 2 rontgen per minute. Marrow donors were identical twins 
in two cases and a mother and sister in one case each. The fifth 
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patient received liver and spleen suspensions of three different 
blood group-identical fetuses and bone marrow from his brother. All 
patients received a second bone marrow infusion sifter 11 or more 
days. The total amount of nucleated cells Infused varied from 9.6 χ 
I O 9 to 24.0 χ IO 9 cells. Within 22 days after irradiation three 
patients died from infection and one twin marrow recipient died 
from hepatic failure. At autopsy no evidence of leukemia was found 
and the recipient of maternal marrow and the twin marrow 
recipient showed signs of marrow regeneration. The only patient 
who survived 22 days received a graft from his identical twin 
brother. Marrow function recovered and he was discharged from 
the hospital on the 42d postirradiation day. He died from relapsed 
leukemia 72 days after BMT. In their comment the authors 
discussed that in one patient take failure may have been related to 
pretransplant sensitization to foreign cells by blood transfusions 
and that the transfusion of fresh blood products might have been 
the cause of graft failure in another patient. In order to avoid the 
latter complication they proposed to irradiate fresh blood or 
platelets with 500 to 1,000 röntgen before administration. 
In 1963 Mathé et al t ransplanted a 26-year-old man with 
relapsed acute lymphoblastic leukemia.22 He was pretreated with 
azathloprine 300 mg daily for 4 days followed by 400 röntgen of 
total body Irradiation given on each of two consecutive days. A 
mixture of equal parts of bone marrow from six donors (his father, 
mother, three brothers and a sister) to a total dose of 58 χ IO 9 
nucleated cells was given intravenously. Fifteen days after the 
Infusion of bone marrow cells polymorphonuclear cells began to 
rise. In the mean time marked diarrhea had occurred followed by 
generalised eruption and desquamation of the skin. The patient had 
fever. Skin biopsy showed laesions typical of secondary syndrome. 
Because of hepatic dysfunction corticosteroids were started. Patient 
recovered completely. Using red cell phenotyping it was shown 
that the erythrocytes had the phenotype of one of his brothers, 
with studies of the leukocyte sex chromatlne a few female cells 
were found and Immunoglobulin phenotyping showed donor-type 
globulins (all bone marrow donors had the same immunoglobulin 
phenotype). At 44 days posttransplant the patient received skin 
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grafts from all bone marrow donors. The skin graft of the sister 
donor was lost by accident and all but the skin graft of the brother 
donor whose red cell phenotype the patient had acquired had been 
rejected at 60 days. This skin graft remained perfectly intact for 
more than seven months. Five months after transplantation blood 
leukocytes from this brother were given intravenously in order to 
enhance the presumed anti-leukemic effect of the graft against the 
host. A total number of 163 χ IO 9 leukocytes were given at 4 one-
week separated occasions. Recurrence of secondary syndrome was 
suggested and was successfully treated with corticosteroids. About 
3 months after the infusion of donor leukocytes, he developed 
widespread necrotic herpes zoster complicated by meningo­
encephalitis. The patient died 20 months posttransplantation. Post­
mortem examination was without evidence of leukemia. 
This patient was one of the 21 summarized in 1967 by Mathé et 
aL2 3 These patients with acute lymphoblastic leukemia in remission 
or in active phase were irradiated with 793 to 950 rads and most of 
them received pooled bone marrow from up to 6 different related 
and unrelated donors. Transplantation of grafts from several donors 
was based on experiments In mice showing that simultaneous 
infusion of bone marrow resulted in engraftment of marrow from 
the genetically most close donor.24 Five patients died in aplasia, a 
sixth patient survived aplasia after retransplantation with a graft 
from his monozygotic twin. Fifteen patients showed engraftment 
and all suffered from secondary syndrome causing death in 11 
patients. Four patients survived the secondary syndrome but died 
from leukemia.25 
THE HUMAN LEUKOCYTE ANTIGEN (HLA) SYSTEM 
The major breakthrough in the prevention of secondary disease was 
the discovery of the genetic principle of histocompatibility. In 1953 
Snell et al demonstrated that susceptibility and resistence to bone 
marrow transplantat ion in mice were determined by multiple 
dominant genes, the histocompatibility genes . 2 6 One of these 
dominant genes was called the H-2 locus. Uphoff observed that 
differences in histocompatibility genotypes at this locus were 
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responsible for secondary disease. 2 7 According to Snell et a l 2 8 the 
human histocompatibility locus was called H u - 1 . 2 9 · 3 0 Leukocytes 
were carrying transplantat ion a n t i g e n s 3 1 · 3 2 and these could be 
d e m o n s t r a t e d by · t h e lymphocytotoxlcity t e s t 3 3 and by 
l e u k o a g g l u t l n a t l o n . 3 4 The antibodies used were obtained from 
multiparous w o m a n 3 5 or from volunteers specifically immunised 
against leukocytes. Apart from serologic typing for specific 
histocompatibility antigens, the degree of compatibility between 
Individuals could be assessed by the one-way mixed leukocyte 
culture (MLC) test. In the MLC test, donor leukocytes have been 
treated with mitomycin С which prevents them to proliferate yet 
allows them to stimulate untreated leukocytes of the recipient . 3 6 
This stimulation can be measured by incorporation of trltiated 
thymidine. Using these methods the number of leukocyte antigens 
that could be recognized increased and this resulted in more 
Insight in the very complex system of histocompatibility in 
m a n .
2 9
·
3 0
·
3 3
·
3 7
"
4 0
 Standardization of different technologies and of 
nomenclature had been performed from 1964 onward at the 
International Histocompatibility Workshops. At the third workshop 
in 1967 the human histocompatibility system was recognized as 
one major human leukocyte antigen (HLA) complex. The complexity 
of the HLA system resulted in a very high number of possible 
phenotypes. Furthermore it was found that recipient and donor 
combinations, serologically Identical for HLA antigens, could be 
positive in MLC testing, indicating that HLA loci existed which 
could not be recognized serologically yet . 4 1 In the following years it 
became evident that one single region localised on the short arm of 
the sixth chromosomes determined the transplantation antigens. 
This region was called the major histocompatibility complex 
(MHC). The MHC consisted of two groups of genetically separable 
loci determining the strong transplantation antigens which could 
be demonstrated serologically using antisera to detect cell-surface 
specific antigens (the HLA-A, HLA-B and HLA-C antigens) and by a 
cellular approach such as the reactivity of lymphocytes In the MLC 
test (the HLA-D antigens) . 4 2 " 4 4 
In 1970 Bortln summarized 203 reported human bone marrow 
t ransp lants performed for aplastic anemia (N=73), leukemia 
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(N=84), other malignant diseases and miscellaneous conditions 
(N=31), and Immune deficiency diseases (N=15).45 More than 
three quarters of these transplantations were performed between 
1959 and 1962 and since it had become evident that outcome was 
very disappointing, the number of reported transplants decreased 
to 49 between 1962 and 1968. In at least 125 patients (62%) 
engraftment did not occur and 152 (75%) were dead at the time of 
the case report. Donor selection was based on the one-way MLC test 
in only three of the 203 patients and these three received a graft 
from an HLA-identical sibling. They were transplanted for immune 
deficiency disease and were the only reported allogeneic bone 
marrow chimeras who were still alive at 150 to 365 days. 
Histocompatibility testing between recipient and donor was not 
performed in 200 transplants and only two of these transplants 
were successful. In both cases donors were siblings. 
BONE MARROW TRANSPLANTATION WITH HLA-SELECTED 
DONORS 
In 1968 Bach et al46 and Gatti et al47 described a successful bone 
marrow transplantation in man using an HLA-identical sibling 
donor. Identity was based on the lymphocytotoxicity test and MLC 
test. The patient of Bach et al was a 2-year-old boy with the 
Wiskott-Aldrich syndrome. His lymphocytes responded normally to 
PHA and lymphocytes of an unrelated donor. Bone marrow donor 
was his MHC-identical 8-year-old sister. At about 4 weeks 
posttransplantation bone marrow aspiration showed a cellular 
marrow with a normal differentiation. Chromosome studies of blood 
lymphocytes showed 100% donor cells. Follow-up ended 6 weeks 
after transplantation and no graft-versus-host disease (GVHD) was 
observed. 
The patient of Gatti et al was a 5-month-old boy with sex-linked 
lymphocytopenlc immunological deficiency. Lymphocytes of the 
patient did not respond to PHA and allogeneic cells. Although his 
lymphocytes had one antigen which was not present on the 
lymphocytes of his 8-year-old sister, she was considered a MHC-
compatible donor since the MLC from donor to patient cells 
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showed complete absence of response. Without pretreatment IO 9 
nucleated bone marrow cells were given intraperitoneally. After 
nine days a rash developed with biopsy proven findings typical of 
graft-versus-host disease (GVHD) which subsided spontaneously. 
Thereafter he had loose stools with small ulcers on proctoscopy 
and a biopsy showed laeslons characteristic of GVHD. From the day 
of administration of donor cells on, white blood cell count 
decreased but stabilised at 2 χ 109/L. Chromosome studies on 25 
unstimulated bone marrow cells showed 18 male and 7 female 
chromosomes. Both humora l and cellular immunological 
r e c o n s t i t u t i o n o c c u r r e d . However, the p a t i e n t b e c a m e 
pancytopenic and was successfully retransplanted with 1 0 9 
nucleated bone marrow cells from the same donor given both 
intraperitoneally and In the right posterior iliac crest resulting in 
100% red and white blood cell chimerlsm. 4 8 
It had become evident t h a t success of bone marrow 
transplantation was dependent on the clinical condition of the 
recipient at t ransplantat ion, on histocompatibility matching 
between recipient and donor, on conditioning regimen, on 
supportive m e a s u r e s both in the period before and after 
engraftment and on the treatment of GVHD. This knowledge 
renewed interest In clinical bone marrow transplantation at the 
end of the sixties. 
In 1971 Thomas et al described transplantation in seven patients 
with malignancies refractory to conventional t rea tment . 4 9 Two had 
advanced acute myeloid leukemia and one had chronic myeloid 
leukemia in blast crisis. Three patients with acute lymphoblastic 
leukemia and one with Hodgkln's disease had less advanced disease 
and were in good clinical condition. The sibling donors were HLA-
identlcal and the one-way mixed leukocyte test was negative in 6 
pairs and showed only minimal stimulation in one donor-recipient 
combination. Five patients were nursed in laminar air flow isolation 
rooms with sterilisation of the skin, food and gut. They used 
antibiotic sprays for ears and nose as well as mouth rinses with 
antibiotics and antifungal drugs. Conditioning consisted of 1,000 
rad of total body irradiation at a dose-rate of 5.0 to 5.7 rad/min. In 
order to prevent rejection and to ameliorate GVHD the patients 
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received methotrexate 10 m g / m 2 on days 1, 3, 6 and 11 and 
weekly thereafter. Platelets, buffy coat cells and whole blood cells 
were irradiated with 1500 rad before infusion. None of the 3 
patients treated for advanced leukemia reached white blood cells of 
> 1.0 χ 10 9 /L nor suffered from GVHD, but all died within 30 days 
from renal failure or septicaemia. In the 4 patients treated for less 
advanced disease white blood cells rose over 1.0 χ 10 9/L and all 
suffered from GVHD. Two died from recurrent leukemia at 85 and 
102 days after t ransp lanta t ion, respectively. The pat ient 
transplanted for Hodgkln's disease engrafted but died from GVHD 
at 37 days posttransplant. One patient survived with 100% donor 
cells and returned to school 200 days after transplantation. 
In 1972 Thomas et al reported on successful sibling bone 
marrow transplantation in 2 of 4 patients transplanted for aplastic 
a n e m i a . 5 0 They had received multiple blood transfusions and were 
refractory to conventional treatment. Donors were MHC-identical 
and sex-mismatched siblings. P r e t r e a t m e n t consisted of 
cyclophosphamide 50 mg/kg body weight on each of 4 consecutive 
days according to Santos et al.51 Patients were given one unit of 
buffy coat cells from the bone marrow donor on the day before 
cyclophosphamide administrat ion in order to enhance the 
i m m u n o s u p p r e s s i v e effect of c y c l o p h o s p h a m i d e . 
Immunoprophylaxls posttransplant consisted of methotrexate. The 
first patient died from sepsis complicating GVHD. The second 
patient had no GVHD and at 29 days he had mixed chimerism in 
PHA-stimulated peripheral blood cells b u t complete donor 
chimerism in unstimulated bone marrow cells. In further follow-up 
cytogenetic analysis of both blood and bone marrow metaphases 
showed 100% donor cells. The third patient rejected the graft and 
was retransplanted. He was pretreated with cyclophosphamide 50 
mg/kg intravenously on each of 4 consecutive days together with 
anti-human thymocyte serum but died from widespread Candida 
infection. The fourth patient had low grade GVHD disease and 
recovered completely. Repeated cytogenetic analysis showed 100% 
donor metaphases in both blood and bone marrow cells. Thomas et 
al proposed to transplant patients with aplastic anemia and an HLA-
identical sibling early in the course of the disease before major 
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infections and hemorrhage or sensitisation to transplantation 
antigens had occurred. 
The Seattle transplant center described its experience on 100 
patients with end stage acute leukemia and transplanted between 
1971 and 1975. Those in good clinical condition had a significantly 
longer survival time than patients transplanted in poor clinical 
cond i t ion . 5 2 Prior treatment consisted of several courses of 
combination chemotherapy, but 19 patients never achieved 
complete remission and only 10 had < 5% leukemic blasts In the 
bone marrow at the time of transplantation. Donors were MHC-
identlcal siblings in 99 cases and one МНС-identical cousin who 
shared the four grandparents with the recipient. In an effort to kill 
more leukemic cells 1,000 rad total body irradiation In a single 
dose was preceded by cyclophosphamide 60 mg/kg intravenously 
on each of two consecutive days with or without the addition of 
other cytostatic drugs. In 6 cases, cyclophosphamide was omitted. 
Methotrexate was administered in order to prevent and/or to 
ameliorate GVHD. Six patients died within 17 days without 
evidence of engraftment. Ninety-four patients engrafted but one 
rejected the graft. GVHD grade II or more developed in 50 patients 
and was treated with one or more courses of anti-thymocyte 
globulin in 38 cases. Interstitial pneumonitis occurred in 54 
patients and was lethal in 34. Both the incidence of interstitiell 
pneumonitis and death from interstitial pneumonitis was higher in 
patients with acute GVHD ä grade II. Thirty-one patients relapsed 
from leukemia. Due to the large number of deaths, no relation was 
found between relapse of leukemia and the presence or absence of 
GVHD. Seventeen patients survived for 330+ to 1654+ (median 
892+) days but four of them had relapsed at 210 to 833 days. The 
actuarial survival curve could be divided into three time Intervals: 
the first 130 days with a high death-rate mainly due to GVHD and 
infections. A second period between 130 days and two years with 
less overall mortality and death mainly due to relapses, and a 
plateau phase from 2 to 4.5 years without deaths, although 4 of 17 
patients had a relapse of the leukemia. 
The overall results were poor and it was evident that this was due 
to the poor clinical condition of the patients suffering from end-
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stage leukemia. The Seattle group observed a significant 
improvement in survival in pat ients t ransplanted for acute 
lymphoblastic leukemia in second or subsequent remission 
compared to those transplanted in relapse.5 3 Dinsmore from the 
group of the Bone Marrow Transplant Center of the Memorial 
Sloan-Kettering Cancer Center showed that disease-free survival 
had improved in patients transplanted for acute lymphoblastic 
leukemia in second remission in comparison with those 
transplanted in later remission or relapse.5 4 The Seattle center 
reported on good outcome of bone marrow transplantation in 
patients transplanted for acute myeloid leukemia in first complete 
remission.5 5 The probability of disease-free survival was 63% with 
12 of 19 patients living without relapse for more than 471 days 
after transplantation. These results were comparable with those 
obtained in Europe.5 6 Outcome of bone marrow transplantation in 
CML patients was disappointing when performed after onset of 
blast cr is is ,5 7 but Improved when patients were transplanted in 
first chronic phase. 5 8 
GRAFT-VERSUS-HOST DISEASE (GVHD) 
Attempts have been made to reduce the incidence of GVHD. In 
1963 Mathé et al showed that preservation of hematopoietic cells 
for 2 hours at 37° С reduced the incidence of secondary syndrome 
in mice without affecting the restoration capacity of myeloid cells. 5 9 
Van Bekkum demonstrated that mortality due to graft-versus-host 
reaction was a function of the number of lymph node cells infused. 
Storage of a mixture of bone marrow cells and lymph node cells at 
4 С for 24 to 48 hours had a more profound inactivating effect on 
the immunologically active cells than on the hematopoietic cel ls . 6 0 
Epstein et al found a reduced severity of the secondary disease 
when dogs had been treated with methotrexate in the early period 
of engraftment. 6 1 Cyclophosphamide or antilymphocytic antisera 
given to monkeys after bone marrow infusion controlled secondary 
disease only partially. 6 2 Harris and Joseph separated bone marrow 
cells in fractions by differential centrifugatlon in a density gradient 
composed of fractions of different concentrations of bovine plasma 
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albumin. 6 3 They found the earliest forms of blasts cells, myeloblasts, 
promyelocytes and proerythroblasts together with lymphocyte-like 
cells in the upper two layers with the lowest density. In the middle 
two layers granulocytes and lymphocytes predominated and 
normoblasts and eosinophils were found in the deepest two layers. 
The separation of cells had not damaged their viability since rapid 
recovery was found in animals infused with these recombinated 
bone marrow fractions. In 1968 Dicke et al assessed the 
repopulation capacity and graft-versus-host activity of the various 
fractions of mouse spleen cell suspensions after separation on a 
discontinuous albumin gradient . 6 4 In comparison to the original 
spleen cell suspension they observed a ten-fold increase in the 
concentration of spleen colony forming units and more than a 10-
fold decrease of graft-versus-host activity after infusion of the 
pooled upper layers containing between 30% and 50% of the total 
number of erythroblasts, myeloblasts and other blast cells. Mice 
infused with cell fractions from the intermediate layers containing 
lymphocytes, granulocytes and a small number of blast cells, died 
from secondary disease. Those infused with fractions from the 
lower layers containing lymphocytes and granulocytes, died from 
graft failure. Since the lower layers had the lowest hematopoietic 
capacity, they concluded that the putative hematopoietic stem cells 
were not small lymphocyte-like cells. 
The clinical manifestations and grading of acute GVHD had been 
described by Glucksberg et a l . 6 5 Acute GVHD typically developed 
within 3 months after t ransplantat ion and was caused by 
immunocompetent Τ lymphocytes present in the graft and directed 
against alloantlgens expressed on host cells leading to tissue injury. 
Acute GVHD was found in 30 to 70% of recipients of an HLA-
identical marrow graft and caused death in 20 to 40% of those 
affected.6 6 Shulman and Sullivan summarized the clinical course of 
chronic G V H D . 6 7 · ^ Chronic GVHD developed more than three 
months after t ransplantat ion and resembled a n autoimmune 
disorder with skin pathology resembling scleroderma, abnormal 
liver tests, ocular and oral symptoms resembling Sjogren's 
syndrome, pulmonary insufficiency, and manifestations In other 
organs. Chronic GVHD was observed in 52 of 175 (30%) transplants 
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and was lethal in 17 (33%) p a t i e n t s . 6 8 GVHD and associated 
infections remained the major obstacles to success of bone marrow 
transplantation. 
The Seattle group used methotrexate as standard prophylaxis for 
acute GVHD but this was only partially effective.69 Prophylactic 
administration of anti-thymocyte globulin had no beneficial effect.70 
Established acute GVHD was treated with corticosteroids with or 
without the addition of anti-thymocyte globulin but was inadequate 
in many c a s e s . 7 1 · 7 2 Cyclosporine A with its selective inhibitory 
activity on activated Τ cells was initially used by Powles et al for the 
t reatment of GVHD 7 3 but later on for prevention of GVHD. 7 4 
Randomised trials comparing methotrexate and cyclosporine A as 
prophylaxis for GVHD did not show significant differences in the 
incidence of moderate and severe acute nor chronic GVHD in 
patients transplanted for acute l e u k e m i a 7 5 · 7 6 or chronic myeloid 
leukemia. 7 7 When compared to cyclosporine alone, the combination 
of cyclosporine A and methotrexate decreased significantly the 
incidence of moderate and severe acute GVHD but not of chronic 
GVHD in transplants for acute myeloid leukemia in first remission 
or CML in first chronic p h a s e . 7 8 
Another approach to prevent GVHD is the in vitro depletion of 
immunocompetent Τ lymphocytes from the donor marrow. This 
can be accomplished by immunological or physical methods. 
Immunological methods of Τ cell depletion. Rodt et al incubated 
donor marrow with anti-human Τ cell globulin to remove Τ cel ls . 7 9 
GVHD grade I-II was observed in only 2 out of 12 engrafted 
patients. In a pilot study on 10 consecutive patients, Filipovich et al 
showed that histocompatible sibling donor marrow could be safely 
infused after pretreatment with OKT3, an IgG2a complement-
binding mouse monoclonal antibody specifically directed against Τ 
l y m p h o c y t e s . 8 0 In vitro studies demonstrated that almost all Τ 
lymphocytes were coated with OKT-3 and subsequent incubation 
with neonatal rabbit complement reduced PHA response to 4% of 
that of untreated bone marrow samples. However, 5 out of 10 
patients developed GVHD grade II or more and this was due to the 
inability of autologous human complement to eliminate OKT-3 
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coated cells in vivo. Prentice et al observed a reduced incidence of 
severe acute GVHD In recipients of marrow grafts pretreated with 
OKT3. 8 1 In vitro lysis with complement was not performed and all 
patients received methotrexate as graft-versus-host prophylaxis 
posttransplant. They also showed that incubation of the marrow 
graft with a combination of two monoclonal antibodies followed by 
two rounds of lysis with rabbit complement killed > 99% of Τ cells 
in all b u t one graft and prevented significant G V H D . 8 2 
Immunoprophylaxls posttransplant was not given. A mixture of 
eight monoclonal antibodies providing optimal antibody binding to 
all Τ lymphocytes and lysis with two rounds of rabbit complement. 
was used by Martin et al from Seattle resulting in a 2 to 3 logs 
depletion of Τ cells in most p a t i e n t s . 8 3 Prophylaxis after 
transplantation consisted of cyclosporine A. The incidence and 
severity of acute GVHD disease had decreased significantly 
compared with controls. However, Τ cell depletion was associated 
with an Increased incidence of graft failure. 
Other antibody-mediated techniques for in vitro depletion of Τ 
lymphocytes were reported such as antibodies coupled to ricin 
toxin, 8 4 and antibodies coupled to magnetic microspheres. 8 5 " 8 7 
Physical methods of Τ cell depletion. Several physical methods have 
been developed to remove lymphocytes from donor marrow. Bone 
marrow was fractionated by soybean agglutinin and sheep red blood 
cel l s , 8 8 - 9 1 density gradients, 9 2 and counterflow elutriation. 9 3 
Reisner et al eliminated Τ cells from the leukocyte-enriched 
fraction of bone marrow by E-rosettlng with sheep red blood cells 
followed by differential agglutination of residual Τ lymphocytes in 
the non-rosetting fraction with soy bean agglutinin, a plant lectin 
that selectively removes Τ lymphocytes. 8 8 In a modification of this 
method, the leukocyte-enriched fraction was treated first with 
soybean agglutinin followed by depletion of residual Τ cells from the 
unagglutlnated fraction by E-rosetting with sheep red blood 
c e l l s . 8 9 · 9 0 The non E-rosetting cells contained 5% of the nucleated 
cells of the original marrow, more than 80% of the colony forming 
cells, and no detectable Τ lymphocytes. Using this modification 
O'Reilly et al transplanted 22 patients with a graft from an HLA-
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identical donor. 9 1 Conditioning consisted of cyclophosphamide 
(120 mg/kg) and hyperfractionated total body irradiation to a dose 
of 13.2 Gy. No additional immunoprophylaxis was given. Twenty 
patients achieved a durable full engraftment and 16 survived 
disease-free 3 to 10 months posttransplant . Only one patient 
suffered from GVHD grade II. 
Löwenberg et al observed a significantly higher incidence of acute 
GVHD S grade I in patients receiving marrow grafts depleted of 
90% of lymphocytes using discont inuous albumin gradient 
fractionation when compared to those given transplants depleted of 
99% of lymphocytes using E-rosette sedimentation.92 The authors 
referred to studies in monkeys where it had been calculated that 
mortality due to GVHD without additional immunosuppression 
pos t t ransplanta t ion in МНС-identical t ransp lant s , could be 
prevented fully if not more than 2 χ ΙΟ 6 Τ lymphocytes/kg body 
weight were given. 9 4 
Another physical depletion method is counterflow centrifugation 
(elutriation). Counterflow centrifugation separates cells mainly 
according to their s i z e . 9 3 · 9 5 " 9 8 In summary: bone marrow is filtered 
through a nylon filter with a pore size of 70 μτη.. After removal of 
plasma and fat, a mononuclear cell fraction with a density < 1.073 
g/ml is isolated in gradients of Percoli (Percoli, Uppsala, Sweden). 
Then the low density mononuclear fraction is pumped into the 
s e p a r a t i o n c h a m b e r which is placed excentrically In a 
centrifugation rotor. The separation capacity of the original single 
chamber rotor (Beekman JE-6) h a s been enhanced by the 
development of a multiChamber counterflow centrifugation system 
with four separation chambers reducing the total time of the 
elutriation procedure to about 3 h o u r s . 9 9 The transparant chambers 
(International Medical BV, Zutphen, The Netherlands) have been 
placed in a rotor (type Mark-l , Dijkstra Vereenlgde BV, 
Amsterdam, The Netherlands) t h a t h a s been installed in a 
modification (Curame-3000) of the Varifuge-RF centrifuge (Heraeus 
Separatlonstechnic, Ostenrode Germany). The particles in the 
separation chamber are subjected to two opposing forces: the 
centrifugal force depending upon the rotor speed and the 
centripetal force caused by the continuous fluid stream pumped 
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into the chamber with a direction towards the rotor axis. At 
equillibrium the cells are positioned according to their size with 
the larger cells in the more centrifugal position and the smaller 
cells in the more centripetal direction. By increasing the 
centripetal force and/or decreasing the centrifugal force this 
equilibrium shifts towards the outlet of the chamber and the 
smaller cells are the first to leave the chamber. The rotor outlets 
are monitored for cell number using a Ortec-541 ratemeter (EG7G 
Ortec. Oak Ridge, Tennessee, USA) and for cell size using a 
mult ichannel analyser ND 600 (Nuclear Data Incorporated, 
Schaumberg, Illinois. USA). The cells are collected In several 
fractions and of each fraction the numbers of nucleated cells are 
measured. Of each fraction the number of Τ lymphocytes are 
counted using a Coulter Epics Elite (Coulter Corporation, Hialeah, 
Fl. USA) after binding to CD3-FITC monoclonal antibody (Dakopatts. 
Glostrup, Danmark). The marrow that Is ultimately given to the 
recipient consists of the larger cells fractions with an absolute total 
number of Τ cells between 0.7 and 1.0 χ 106/kg body weight of the 
recipient corresponding to a Τ cell depletion of about 98%. The 
first clinical resul ts of bone marrow t ransplantat ion us ing 
counterflow centiifugatlon at the University Hospital Nijmegen have 
been described by De Witte et al in 1984. 9 7 Two of the first six 
patients died within 22 days due to infections and despite the 
average high age of 30 years only one of the 4 patients at risk 
developed acute GVHD grade II. He was one of two patients who did 
not receive additional Immunosuppression. 
GVHD AND RELAPSE OP LEUKEMIA 
In 1957 Barnes and Loutlt showed that mice irradiated with 950 
rads followed by transplantation with sjmgeneic bone marrow 
usually died after about one month with overt leukemia but those 
transplanted with allogeneic marrow often survived for longer 
periods and ultimately died in wasted condition but without signs of 
l e u k e m i a . 1 2 They considered that an immune reaction of the 
allograft had destroyed residual leukemic cells but also acted on 
normal tissue causing the secondary phenomenon (GVHD). The 
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influence of GVHD on relapse of leukemia was analysed in 242 
t ransplants for acute leukemia performed between 1970 and 
1 9 7 8 . 1 0 0 Forty-six patients received a syngeneic graft and 196 were 
transplanted with bone marrow from an allogeneic donor. When 
considering type of marrow graft, diagnosis and remission status, 
multivariate analysis showed that patients having moderate to 
severe acute GVHD or chronic GVHD had a significant lower 
relapse-rate than patients with no or mild GVHD. However, the 
positive effect of GVHD on relapse-rate was counterbalanced by a 
higher Incidence of death due to other causes, especially interstitial 
pneumonitis. Consequently, patients with GVHD had no better 
probability of long term survival. In 1981, Weiden et al reported 
that chronic GVHD was associated with a lower relapse-rate and 
improved survival in recipients of allografts for acute leukemia. 1 0 1 
It had become evident that Τ cell depletion of the marrow graft 
was associated with a decreased incidence and severity of GVHD. 
However, recipients of Τ cell depleted marrow had a higher 
probability of relapse. In a prospective randomised double-blind 
trial from the University of California, Τ cell depletion was 
performed using monoclonal Τ cell antibody CT-2, an IgM antibody 
directed against the Ε-rosette receptor antigen on Τ lymphocytes, 
and rabbit c o m p l e m e n t . 1 0 2 Immunoprophylaxis post transplant 
consisted of methotrexate or cyclosporine A. Recipients of Τ cell 
depleted grafts had significantly less mortality due to acute GVHD 
and a significantly lower incidence of chronic GVHD but more 
relapses resulting in equal survival when compared to those 
receiving untreated marrow. Compared to historical controls, 
Apperley et ál found a significantly reduced incidence of acute 
GVHD, but a significantly increased incidence of leukemic relapse 
In 28 recipients of Τ cell depleted grafts transplanted for chronic 
myeloid leukemia in chronic p h a s e . 1 0 3 Donor bone marrow had 
been depleted of Τ cells with the rat-derived monoclonal antibody 
Campath-1 together with fresh serum from the donor as source of 
complement. Τ cell depletion was nearly complete. All but three 
patients were given cyclosporine A as additional prophylaxis against 
GVHD posttransplant. In a prospective randomised trial of Τ cell 
depletion, Maranlnchi et al observed a significant reduction in both 
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acute and chronic GVHD in recipients of Τ cell depleted grafts 
when compared to the patients who received unmanipulated 
m a r r o w .
1 0 4
 Bone marrow was treated with two different 
combinations of monoclonal antibodies and complement removing 
97 to 99% of Τ cells. Immunoprophylaxis posttransplant consisted 
of cyclosporine A. Relapse-rate was significantly higher in 
recipients of Τ cell depleted grafts but disease-free survival did not 
differ between both groups. An average Τ cell depletion of 94% was 
achieved in an open pilot study by Hervé et al using two different 
cocktai ls of pan-T monoclonal an t ibodies wi th r abb i t 
c o m p l e m e n t . 1 0 5 A minority of patients received methotrexate 
posttransplant. The incidence of both acute and chronic GVHD was 
low but relapse-rate appeared to be relatively high. 
The incidence of GVHD and the probability of relapse in 80 
patients transplanted for leukemia with lymphocyte depleted grafts 
using counterflow centrifugation are described in chapter 3 of this 
thesis. The low incidence of GVHD was associated with a relatively 
high probability of relapse. Preliminary data suggested tha t 
intensification of the conditioning regimen with anthracyclines 
reduced relapse of leukemia.1 0 6 A more recent analysis showed a 
probability of relapse of 18% in pat ients conditioned with 
anthracyclines which was slgniflcantly lower than the probability of 
44% in an earlier cohort of 35 comparable patients treated with 
the standard conditioning.107 
BONE MARROW TRANSPLANTATION WITH MATCHED 
UNRELATED DONORS 
A new development in allogeneic bone marrow transplantation is 
the creation of national and international bone marrow donor 
registries. Since about 60% of patients lack an appropriate family 
donor, that means an HLA genotypically identical sibling or a family 
member incompatible at only one locus, voluntary bone marrow 
donors registries have been founded. The chance of finding an HLA-
A, -B, and -DR Identical donor for an individual patient depends on 
the size of the donor pool and the recipients HLA phenotype. It can 
be calculated that the number of possible HLA phenotypes is 
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4 x 1 0 1 8 , but some phenotypes are much more frequent than others 
in a given p o p u l a t i o n . 1 0 8 For example, 17% of North American 
whites with a common phenotype have a 90% probability of finding 
an HLA-A, -B. and -DR matched donor in a registry of 50,000 white 
donors but this is less than 10% for the 48% of potential recipients 
with unusual haplotypes. 1 0 9 The first bone marrow transplantation 
with an HLA-A, -B identical, MLC negative unrelated donor was 
performed in 1973 by Speck et a L 1 1 0 Indication for transplantation 
was severe aplastic anemia. The patient died two months after 
transplantation without signs of engraftment. 
More than twenty registries are operating worldwide and donor 
searches are being performed by computerised systems. At present, 
reports on unrelated bone marrow transplantat ion In acute 
leukemia, myelodysplastic syndromes, and severe aplastic anemia 
are limited. McGlave et al reported on unrelated bone marrow 
transplantation in 102 patients transplanted for CML in first 
chronic phase (CP1) or more advanced d i s e a s e . 1 1 1 In 44 cases of 
HLA-A, -B, and -DR Identical, MLC nonreactive (relative respons 
index < 20%) transplants, actuarial survival was 46 ± 20% at 2.5 
years. This was 27 ± 14% in recipients of less matched unrelated 
donors. Until now, 33 patients have been transplanted with a 
matched unrelated donor in the N e t h e r l a n d s . 1 1 2 Disease-free 
survival at 2 years postgraftlng was 43% in 18 patients transplanted 
for good risk disease. It may be expected that outcome of unrelated 
t r a n s p l a n t a t i o n will improve with b e t t e r match ing and 
transplantation in an earlier phase of the disease. 
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SUMMART 
Eighty consecutive pat ients were t ransplanted with h u m a n 
leukocyte antigen (HLA)-identlcal sibling marrow for acu te 
myelogenous leukemia (AML, N = 29), acute lymphoid leukemia 
(ALL, N = 23), or chronic myelogenous leukemia (CML, N = 28). 
Donor marrow was depleted of lymphocytes using counterflow 
centrifugatlon. Median age of the recipients was 31 years . 
Pretransplant conditioning consisted of cyclophosphamide and 
fractionated total body irradiation (TBI) with a low (4.1 ± 0.3 
cGy/min) or high (13.1 ± 1.6 cGy/min) midline average dose-rate. 
In 43 patients, cytosine-arabinoside or anthracycllnes were added 
to the conditioning regimen. Immunoprophylaxls post transplant 
consisted of methotrexate (MTX) alone, cyclosporine A (CsA) in 
combination with MTX, or CsA alone; two patients received no 
Immunoprophylaxls at all. Graft failure occurred in 4 of 77 évaluable 
patients (5%). The probability of acute graft-versus-host disease 
(GVHD) £ grade 2 at day 100 after transplantation was 15%. The 
projected 3-year estimate of extensive chronic GVHD was 12%. 
Only 3 patients died of cytomegalovirus-interstitial pneumonitis. 
The projected 3-year probability of relapse was 30% (95% 
confidence interval [CI], range 8% to 53%) in transplants for AML 
in first complete remission (CRI), 35% (95% CI, 1% to 69%) after 
transplantation for ALL in CRI, and 38% (95% CI, 2% to 74%) after 
transplantation for CML in first chronic phase (CP1). The projected 
3-year probability of leukemia-free survival (LFS) was 56% (95% CI, 
35% to 77%) after transplantation for AML-CRl. 42% (95% CI, 
16% to 69%) in patients transplanted for ALL-CRl, and 49% (95% 
CI, 18% to 80%) after t ransplanta t ion for CML-CPl. After 
transplantation for AML-CRl. ALL-CRl, or CML-CPl, the median 
follow-up time for leukemia-free survivors was 31+, 30+, and 21+ 
months, respectively. Probabilities of relapse, survival and LFS in 
AML-CRl and ALL-CRl transplants were comparable with those 
reported in recipients of untreated grafts. In patients transplanted 
for CML-CPl. probability of relapse was higher and probability of 
LFS was lower than In recipients of untreated grafts. In transplants 
for leukemia in CRI and CP1, preparat ive regimen and 
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Immunoprophylaxls posttransplant were not associated significantly 
with the probability of acute GVHD à grade 2, extensive chronic 
GVHD, relapse, survival, or LFS. In bone marrow transplantation for 
leukemia, counterflow centrifugation is a useful technique for the 
prevention of GVHD. In transplants for leukemia in CRI and CP1 
receiving Τ cell depleted grafts using counterflow centrifugation, 
probability of survival and LFS can compete with that reported in 
studies from the literature on recipients of untreated marrow. 
Further efforts should be made to reduce relapse-rate, particularly 
in CML transplants. 
INTRODUCTION 
Human leukocyte antigen (HLA)-identical sibling bone marrow 
transplantation (BMT) has become the treatment of choice for 
acute and chronic leukemias. 1 " 7 One of the major obstacles for 
successful outcome is acute graft-versus-host disease (GVHD). It 
occurs in 30% to 70% of HLA-matched recipients and contributes 
to death in 20% to 40% of those affected.2 GVHD, on the other 
hand, reduces the risk of leukemic relapse. 8 The incidence and 
severity of acute GVHD can be reduced by removal of 
immunocompetent Τ lymphocytes from the graft using different 
techniques. 9 Τ cell depletion, however, is associated with Increased 
Incidence of graft rejection and leukemic r e c u r r e n c e . 1 0 · 1 1 
In this article, we report on the outcome of 80 consecutive 
transplants for acute and chronic leukemia. All patients received 
marrow from HLA-identical siblings after lymphocyte depletion 
using counterflow centrifugation.1 2 Results are compared with the 
outcome of BMP with unmanipulated marrow and otherwise Τ cell 
depleted grafts as reported in the literature. 
MATERIALS AND METHODS 
Patient and donor characteristics. From May 1981 through 
September 1988, 80 consecutive pat ients (42 males and 38 
females) were transplanted for acute myelogenous leukemia (AML), 
acute lymphoid leukemia (ALL), or chronic myelogenous leukemia 
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(CML). Marrow donors were HLA-ldentical, mixed lymphocyte 
culture negative siblings (53 males and 27 females). Syngeneic 
transplants were excluded. Median age of the recipients and donors 
was 31 (range 13 to 47) and 32 (range 13 to 51) years. 
respectively. Informed consent was obtained from all recipients and 
donors or their guardians. Donor marrow was depleted of 98% of 
lymphocytes by counterflow centrlfugatlon using a single chamber 
rotor (Beekman Instruments Inc. Palo Alto, CA, USA) 1 3 or a four-
chamber rotor (Dijkstra Vereenigde BV, Amsterdam, The 
Netherlands). 1 4 The absolute number of Τ cells infused ranged from 
0.1 to 3.2 (median 0.7) χ 106/kg body weight. 
Indications for transplantation. The Indications for transplantation 
were as follows: AML in 29 patients (26 in first complete remission 
[CRI]), ALL in 23 patients (17 in CRI), and CML in 28 patients (19 
in first chronic phase [CP1]). 
Conditioning regimen. Standard conditioning regimen consisted of 
cyclophosphamide 60 mg/kg body weight/d (days -6 and -5). In 
order to reduce relapse-rate, cytosine-arabinoside 3 g/m 2 /d (days 
-4 and -3) was added to the standard conditioning regimen in six 
patients and anthracyclines were added in 36 cases (daunorubicin 
26 mg/m 2 /d or demethoxydaunorubicln 7 mg/m 2 /d by continuous 
intravenous (Г ) infusion from days -7 to -2, inclusive). All patients 
received total body irradiation (TBI) in two equal fractions of 450 
cGy each on days -2 and -1 using a 18 MV photon beam linear 
accelerator (Saturne, CGR, Bue, France) with a midline average 
dose-rate of 4.1 ± 0.3 cGy/min in 50 patients, and 13.1 ± 1 . 6 
cGy/min in 30 patients. Lungs and eyes were shielded using 
individually adapted lead blocks. The corrected mean total lung 
dose was 790 ± 1 3 0 and 710 ± 80 cGy for the patients with the 
lower and higher midline average dose-rate, respectively. Donor 
marrow was infused 24 hours after completion of TBI. 
Jmmunoprophylojtfs. Immunoprophylaxis pos t t ransp lant was 
omitted in 2 patients. Since GVHD grade 3 occurred in both 
patients, nine recipients received methotrexate (MTX) according 
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to the Seattle regimen.15 As soon as cyclosporlne A (CsA) became 
available, CsA was added: 30 consecutive patients received both CsA 
and MTX. CsA (3 mg/kg body weight/d) was given by continuous IV 
infusion on days -1 to +28, followed by CsA (9 mg/kg body 
weight/d) orally, with a gradual tapering off after 6 weeks and 
discontinuation after 12 weeks. Weekly IV injections of MTX were 
given from week 5 onward, starting with 2.5 mg /m 2 and weekly 
increments of 2.5 mg /m 2 until a dose of 10 mg/m 2 was reached. 
MTX treatment was discontinued In week 16 after BMT. Since MTX 
delayed engraftment, it was omitted and the next 39 consecutive 
recipients received CsA alone, 3 mg/kg body weight/d by 
continuous IV infusion from days -1 to +14, followed by 2 mg/kg 
body weight/d continuous IV on to day +21. From day +21 onward, 
CsA was given orally in a dose of 6 mg/kg body weight/d to 12 
weeks after BMT, followed by a gradual tapering off and 
discontinuation after 16 weeks postgrafting. All patients were 
managed in single rooms with filtered air under positive pressure 
throughout the transplantation period inside the hospital, and all 
received oral selective gut decontamination, as well as co-
trimoxazole for Pneumocystis carinii prophylaxis and oral acyclovir 
for prophylaxis of herpes infection. 
GVHD. The clinical manifestaUons of acute GVHD were graded 1 
through 4 according to the criteria described by Glucksberg et al.16 
Chronic GVHD was classified as limited or extensive as described by 
Shulman etoL 1 7 
Engraftment. The first day of engraftment was the first of 3 
consecutive days with peripheral white blood cell (WBC) counts of £ 
1.0xl09 /L. Engraftment was proven by the presence of donor-type 
erythrocytes; from 6 months after BMT onward susta ined 
engraftment was also documented by cytogenetic analysis and by 
studies of restriction fragment length polymorphisms (RFLPs).18 '20 
Sta t i s t i cs . Analyses were performed using the Kaplan-Meier 
product-limit method. Actuarial curves were calculated for acute 
GVHD ä grade 2. extensive chronic GVHD, relapse, survival and 
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leukemia-free survival (LFS). The effect of diagnosis on the curves 
was compared using the log rank test and Wilcoxon test. Ρ values < 
0.05 were considered significant. For a particular diagnosis, effect 
of p r e t r a n s p l a n t c o n d i t i o n i n g a n d I m m u n o p r o p h y l a x i s 
posttransplant on the curves could not be studied in multivariate 
analysis: the number of patients In the categories was too small. For 
all diagnoses in CRI and CPl together, however, effect of 
preparative regimen and Immunoprophylaxis posttransplant on the 
curves for acute GVHD > grade 2, extensive chronic GVHD, relapse, 
survival and LFS was studied in univariate and multivariate analysis. 
Variables in pretransplant conditioning and immunoprophylaxis 
posttransplant, évaluable In more than 10 patients, were examined. 
These variables were the lower or higher midline average dose-rate 
of TBI, conditioning with or without anthracycl ines , and 
immunoprophylaxis with MTX + CsA or CsA alone. Association of 
these variables with the Incidence of mixed chimerism was studied 
In univariate and multivariate analysis using the Chi-square test. 
Follow-up ends on date of evaluation (February 1, 1989). 
RESULTS 
Primary engraftment. Three patients died within 22 days after 
transplantation and are not évaluable for engraftment. Two patients 
died at 37 and 44 days without proof of engraftment. Seventy-five 
patients showed WBC engraftment at 7 to 47 (median 19) days after 
BMT. 
Rejection of the marrow graft. Two of the seventy-five patients 
showing engraftment rejected their graft at 2 and 6 months after 
transplantation. Since the first patient, transplanted for AML-CR1, 
had no marker specific for donor-type red blood cells, red cell 
phenotyping could not be used for the demonstration of donor-type 
erythrocytes; cytogenetic analysis or studies with RFLPs were not 
performed. The patient died at day 103 after BMT. In the second 
recipient, transplanted for CML-CP1, donor-type red blood cells 
had disappeared at 6 months after BMT and could not be 
demonstrated at several occasions until end of evaluation. 4 years 
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after BMT. Cytogenetic analysis of bone marrow revealed host-type 
cells only in determinations from 6 to 48 months after BMT 
onward, but repeatedly, 4% of peripheral blood lymphocytes were 
still of donor-type. Using RFLPs. persisting mixed chimerism of 
peripheral blood lymhocytes was confirmed on several occasions. 
Despite the reappearance of the Philadelphia chromosome, the 
patient never showed hematological evidence of relapse. 
Graft failure. Graft failure, defined as failure of primary engraftment 
and early or late rejection of the graft, occurred in 4 of 77 patients 
(5%). 
GVHD. Eleven of seventy-five patients at risk had acute GVHD > 
grade 2 (seven recipients had grade 2, three patients grade 3, and 
one recipient had grade 4). Among them were the 2 patients who 
did not receive immunoprophylaxis posttransplant. The probability 
of acute GVHD > grade 2 at day 100 after BMT was 15% (95% 
confidence interval [CI], range 7% to 23%). Sixteen of sixty-three 
évaluable patients developed chronic GVHD with an extensive 
manifestation in seven. The 3-year probability of extensive GVHD 
was 12% (95% CI, 4% to 21%). For acute and extensive chronic 
GVHD, no significant differences were found in pa t ients 
transplanted for AML-CR1, ALL-CR1, or CML-CP1. In two cases, 
extensive chronic GVHD was preceded by acute GVHD ä grade 2. 
Causes of death. Thirty-five of the eighty patients (44%) died at 8 to 
1,360 (median 114) days after BMT. The principal causes of death 
are shown in Table 1. Three patients died from cytomegalovlrus-
interstitlal pneumonitis.21 
Relapse. Seven patients transplanted for AML (Ν = 29) relapsed at 
3 to 15 (median 6) months after BMT. After transplantation for ALL 
(N = 23), five patients relapsed at 1 to 32 (median 5) months after 
BMT. Seven patients relapsed after transplantation for CML (N = 
28): relapse occurred at 6 to 32 (median 19) months after BMT. 
The projected 3-year probability of relapse for the different 
diagnoses and for the patients transplanted in CRI or CP1 is shown 
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Table 1. Principal causes of death 
Causes N 
Relapse 14 
Aspergillosis 5 
Pneumonia of unknown origin 3 
CMV-IP· 3 
Pneumocystis carinii pneumonia 1 
Candidiasis 2 
ARDS# 1 
Bacterial sepsis 1 
Capillary leakage 1 
Renal fallue 1 
VOD$ 1 
Acute GVHD 1 
Graft-rejection 1 
Total 35 
•Cytomegalovirus-lnterstltlal pneumonitis 
*Adult respiratory distress syndrome 
$Veno-occluslve disease 
In Table 2. Actuarial relapse curves for AML-CR1, ALL-CR1, and 
CML-CP1 are depicted In Fig 1. No significant differences were 
found for the probability of relapse In patients transplanted for 
AML-CR1, ALACRI, or CML-CP1. 
Probability of survival. Sixteen patients t ransplanted for AML 
survived for 4+ to 84+ (median 31+) months; 12 transplants for 
ALL survived for 7+ to 61+ (median 26+) months: and 17 patients 
transplanted for CML survived for 14+ to 59+ (median 23+) months 
after BMT. The projected 3-year probability of survival for the 
different diagnoses and for the patients transplanted in CRI or CP1 
is shown in Table 2; survival curves for AML-CR1, ALL-CR1, and 
CML-CP1 are given in Fig 2. No significant differences were found 
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Table 2. Projected 3-year probability of relapse, survival, 
and LFS in patients transplanted for AML, ALL, and CML 
% Probability (range)· 
Indication/N Relapse Survival LFS 
AML 
all cases/29 
CRI/26 
ALL 
all cases/23 
CRI/17 
CML 
all cases/28 
CP1/19 
36 (14-59) 
30 ( 8-53) 
36 ( 7-64) 
35(1-69) 
57 (24-90) 
38(2-74) 
49 (28-69) 
55 (34-77) 
45(21-69) 
41 (14-67) 
45 (17-73) 
79 (61-97) 
50(31-70) 
56 (35-77) 
47 (23-71) 
42 (16-69) 
32 ( 6-58) 
49 (18-80) 
•95% confidence interval 
Fie 1. Probability of relapse in patients transplanted for AML-CRl, 
ALL-CRl, and CML-CPl. "Пек marks in the relapse curves denote 
leukemia-free survivors 
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for the probability of survival in patients transplanted for AML-CRl, 
ALL-CRl, or CML-CP1. 
Probability of LFS. All 12 patients who relapsed after transplantation 
for AML or ALL died at 33 to 464 (median 49) and 8 to 446 
(median 43) days after relapse occurred, respectively. Four of seven 
patients with a relapse after transplantation for CML, died at 103 to 
591 (median 306) days after diagnosis of relapse. Three are alive at 
49 to 663 (median 638) days elfter relapse occurred. The projected 
3-year probability of LFS for the different diagnoses and for the 
patients transplanted in CRI or CPl is shown in Table 2. Curves of 
LFS after transplantation for AML-CRl, ALL-CRl, and СМЬСР! are 
depicted In Fig 3. No significant differences were found for the 
probability of LFS in paüents transplanted for AML-CRl, ALL-CRl or 
CML-CP1. 
Hematopoietic chimerism. In the present study, hematopoietic 
chimerism was assessed at 6 months after BMT using red blood cell 
phenotyping, cytogenetic analysis, and RFLP studies as described 
Table 3. Number of mixed chimeras and complete donor 
chimeras at 6 months posttransplant. Number and 
occurrence of relapses and follow-up of patients In 
continuous complete remission 
Mixed Complete donor 
chimera chimera 
No patients (%) 31 (61) 20 (39) 
Relapses (%) 5 (16) 6 (30) 
Occurrence of relapse 
range (median)· 12-32 (24) 6-32 (9) 
Follow-up patients In CCR* 
range (median)· 6-61 (24) 6-Θ4 (20) 
•Indicates In months 
^Continuous complete remission 
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previously.2 0 Fifty-one patients with a follow-up of 6 months or 
more did not relapse within 6 months after transplantation. At 6 
months after BMT. 31 (61%) had mixed chimeras and 20 (39%) 
had complete donor chimeras (Table 3). Follow-up of the 31 mixed 
chimeras was 6+ to 61+ (median 24+) months; 5 (16%) relapsed at 
12 to 32 (median 24) months after BMT. Follow-up of the 20 
Table 4. Variables examined for association with the probability of 
acute GVHD ¿ grade 2 said extensive chronic GVHD In univariate 
analysis of patients transplanted for leukemia In CRI and CP1 
Variables 
TBI 
LDR #(N=37) 
HDR $(N=25) 
Anthracyclines 
Without (N=32) 
With (N=30) 
Immunoprophylaxls 
MTX plus CsA (N=21) 
CsA alone (N=31) 
% Probability (Range)* 
Acute 
GVHD > grade 2 
12 ( 1-24) 
24 ( 7-41) 
14 ( 1-27) 
21(6-35) 
10(0-24) 
20 ( 6-34) 
Extensive 
Chronic GVHD 
12(0-24) 
21(2-40) 
3(0-27) 
18 ( 2-34) 
11(0-26) 
17 ( 1-33) 
No significant associations were found. Probability for acute 
GVHD S grade 2 was calculated at 100 days, for extensive 
chronic GVHD projected at 3 years after BMT (corrected for 
patients at risk) 
•95% confidence Interval 
^TBI with the lower midline average dose-rate 
$TBI with the higher midline average dose-rate 
complete donor chimeras was 6+ to 84+ (median 20+) months; six 
(30%) relapsed at 6 to 32 (median 9) months post transplant . 
Similar to our previous analysis on mixed chimerism, no 
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relationship between mixed chlmerism and relapse Elfter BMT was 
observed.2 0 In univariate and multivariate analysis, pretransplant 
conditioning and immunoprophylaxis post transplant were not 
associated significantly with the incidences of mixed chimerism 
(data not shown). 
Variables examined for association with acute GVHD > grade 2, 
extensive chronic GVHD, relapse, survival and LFS in patients 
transplanted for leukemia in CRI and CP1. Although not significant 
in univariate analysis, the probabilities of GVHD s grade 2, extensive 
chronic GVHD. survival and LFS were higher in patients irradiated 
with the higher midline average dose-rate, in patients prepared 
with anthracycllnes and in patients who received CsA alone as 
immunoprophylaxis posttransplant (tables 4 and 5). In multivariate 
Table 5. Variables examined for association with the projected 
3-year probability of relapse, survival and LFS In univariate 
analysis of patients transplanted for leukemia In CRI or CP1 
% Probability (Range)* 
Variables Relapse Survival LFS 
TBI 
LDR #(N=37) 
HDR$(N=25) 
Anthracycllnes 
Without (N=32) 
With (N=30) 
Immunoprophylaxis 
MTX plus CsA (N=21) 
CsA alone (N=31) 
35 (17-54) 51 (34-67) 45 (29-62) 
36 (0-88) 78 (61-95) 52 (9-96) 
39 (19-59) 50 (32-67) 44 (27-61) 
20(0-49) 75(59-91) 63(37-89) 
33(12-55) 62(41-83) 57(36-78) 
24 ( 0-53) 76 (61 -92) 60 (34-86) 
No significant associations were found 
*95% confìdence interval 
^TBI with the lower midline average dose-rate 
*ГВІ with the higher midline average dose-rate 
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analysis, the lowest probabilities of relapse and the highest 
probabilities of acute GVHD à grade 2, extensive chronic GVHD, 
survival, and LFS were found in patients conditioned with both the 
higher midline average dose-rate and anthracyclines and who 
received CsA alone as immunoprophylaxis posttransplant (data not 
shown). Differences, however, were not significant. 
DISCUSSION 
Acute GVHD Is one of the major complications of allogeneic bone 
marrow transplantation. The incidence and severity of acute GVHD 
Is decreased when the graft Is depleted of lymphocytes before BMT. 
Several techniques have been developed for ex vivo elimination of Τ 
lymphocytes. These include antibody-mediated e l i m i n a t i o n , 1 0 · 2 2 - 3 0 
and physical m e t h o d s 3 1 · 3 2 like counterflow centrifugation.1 2 In the 
present study, the probability of acute GVHD > grade 2 at day 100 
after BMT was 15%. This compares favorably with the (actuarial) 
incidence of 39% to 82% in recipients of HLA-identical, 
unmanipulated g r a f t s . 2 2 " 2 5 · 2 7 · 3 1 In studies on HLA-identical. Τ cell 
depleted transplants, (actuarial) incidence of acute GVHD > grade 2 
varied from 0 to 5 0 % . 2 2 - 2 9 · 3 1 · 3 2 The paUents in the different 
studies, however, are not comparable with regard to risk factors for 
acute GVHD such as pretransplant diagnosis . 3 3 older age of the 
r e c i p i e n t , 2 6 · 3 3 · 3 4 s e x - m i s m a t c h , 3 3 · 3 4 and immunoprophylaxis 
p o s t t r a n s p l a n t . 3 4 Furthermore, In recipients of Τ cell depleted 
grafts, the number of Τ cells infused can be factors of r i s k . 2 6 · 3 2 · 3 5 " 3 9 
In the present study, the 2-year probability of chronic GVHD and 
its extensive manifestation was 25% and 12%, respectively. Chronic 
GVHD occurred In 39 to 62% of recipients of HLA-identical, 
unmanipulated grafts. 2 2.25.27 -with an extensive manifestation In 35 
to 54% of c a s e s . 2 3 · 2 4 In HLA-identical. Τ cell depleted transplants, 
these percentages varied from 0 to 3 0 % . 2 2 . 2 5 - 2 8 . 3 1 · 3 2 and from 0 to 
11%, respect ively . 2 3 " 2 5 · 2 8 · 3 1 · 3 2 
Lymphocyte depletion of the marrow graft is associated with a 
higher incidence of graft failure: graft failure occurred In 0 to 35% 
of HLA-ldenücal, Τ cell depleted t r a n s p l a n t s 1 0 · 2 2 · 2 3 · 2 5 - 2 ^ ! ^ . « 
and in 0 to 1% of recipients of HLA-identical. unmanipulated 
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m a r r o w .
1 0
·
2 2
·
2 3
·
2 5
·
2 7
 In recipients of Τ cell depleted grafts, an 
Immunologic advantage is created for the host resulting in a higher 
risk of graft failure. In order to prevent this, additional 
pretransplant immunosuppression of the host is required. This can 
be achieved by in vivo application of monoclonal antibodies directed 
against conditioning regimen surviving host-immunocompetent 
cel ls , 4 1 by application of a higher total dose of fractionated TBI or 
by TBI in a single d o s e . 1 0 · 4 0 Certain donor derived Τ cells or their 
products can facilitate engraftment by suppressing residual host 
cells and/or by promoting hematopoietic stem cell growth. This 
can be accomplished by infusion of irradiated donor buffy coat after 
B M T . 4 2 In the present study, graft failure occurred in 5% of 
pat ients . Two mechanisms may be responsible for this low 
incidence: the number of Τ cells left in the graft and the relatively 
high midline average dose-rate in 50 patients. 
Lymphocyte depletion of the marrow graft is associated with a 
higher relapse-rate: after transplantation for leukemia in CRI or 
CPl, probability of relapse varied from 17% to 60% in recipients of 
HLA-identical, Τ cell depleted g r a f t s 2 2 · 2 7 · 4 3 - 4 5 and from 7 to 35% 
In HLA-identical, unmanipulated t r a n s p l a n t s . 2 2 · 2 7 · 4 3 - 4 5 In the 
present study, the projected 3-year probability of relapse after 
transplantation for AML-CR1, ALL-CR1. or CML-CP1 was 30%, 35%. 
and 38%, respectively. Differences in relapse-rate between 
t ransp lants with and without GVHD, suggest that GVHD is 
associated with an antileukemic e f f e c t . 1 · 2 · 8 · 9 · 1 1 · 4 3 · 4 6 Butturini and 
G a l e 4 6 reported on a novel anti leukemic mechanism after 
transplantation for CML in chronic phase: recipients of Τ cell 
depleted, HLA-identical t ransplants had a higher incidence of 
relapse than syngeneic transplants, suggesting that the removal of 
immune cells, probably Τ cells, is responsible for a higher relapse-
rate. Slavin et al47 observed a severe suppression of the generation 
of interleukin-2-induced cytotoxic lymphocytes against natural 
killer (NK)-resistant and NK-sensitive target cells after 
pretreatment of human bone marrow cells with Campath-1M. An 
analysis of the International Bone Marrow Transplant Registry 
( I B M T R ) 4 8 showed that recipients of Τ cell depleted marrow 
without GVHD had a 2-year probability of relapse of 54%, which was 
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higher than the 22% observed In patients receiving unmanipulated 
grafts without GVHD. Simultaneously with Τ cell depletion, cells 
with antileukemic activity or producing antileukemic factors may be 
eliminated. 
Attempts to decrease leukemic relapse after Τ cell depletion 
include intensification of the pretransplant regimen, 4 9 infusion of 
i r radiated donor buffy coat after B M T , 4 2 omiss ion of 
immunosuppressive drugs posttransplant, and the enhancement of 
donor- or host-derived NK and lymphokine-activated killer (LAK) 
f u n c t i o n . 5 0 In our pat ients, preliminary d a t a suggest t h a t 
intensification of the conditioning regimen with anthracycllnes may 
reduce leukemia relapse. 5 1 
In transplants for leukemia in CRI or CP1, the probability of LFS 
varied from 2 9 % to 74% in recipients of HLA-identical, 
unmanipulated grafts 7.27.45.52-56 and f
rom
 370,6
 t o 530/0 after 
transplantation with HLA-identical, Τ cell depleted g r a f t s . 2 7 ' 4 4 · 4 5 In 
a recent study from the IBMTR on HLA-identical bone marrow 
transplantation, 5 7 5-year probability of LFS after BMT for AMI^CRl, 
ALL-CR1, or CML-CP1 was 48%. 4 3 % and 41%, respectively. The 
majority of these patients received unmanipulated marrow. In the 
present study, the 3-year projected LFS for AML-CR1, ALL-CR1, or 
CMLrCPl was 56%, 42% and 49%. respectively. Median follow-up 
time for leukemia-free survivors after transplantation for AML-CR1, 
ALL-CR1 and CML-CP1 was 31+, 30+ and 21+ months, respectively. 
In comparison with studies from the literature on recipients of 
untreated marrow, patients receiving Τ cell depleted grafts using 
counterflow centrlfugatlon have a lower incidence and severity of 
GVHD. The lower GVHD-related mortality is counterbalanced by an 
increase of graft failure and relapse. In the present study, the 
probability of survival and LFS after transplantation for leukemia In 
CRI and CP1 can compete with that reported in studies from the 
literature on recipients of untreated grafts. Further efforts should 
be made to reduce relapse-rate, particularly in CML transplants. 
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CHAPTER 4 
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SUMMARY 
Using red cell phenotyping, cytogenetic analysis of blood 
lymphocytes, chromosome studies of bone marrow cells, and 
restriction fragment length poljnmorphisms (RFLPs) studies of 
peripheral blood cells, we demonstrated a high number of mixed 
chimeras after allogeneic bone marrow transplantat ion (BMT). 
Donor marrow from HLA-A, -B, and -DR identical, mixed 
lymphocyte culture (MLC) negative siblings was depleted of 98% of 
lymphocytes using counterflow centrifugati on. Thirty-two of 48 
recipients (67%) appeared to be mixed chimeras at 6 months after 
transplantation. The high number of mixed chimeras is probably a 
result of lymphocyte depletion of the marrow graft and the high 
sensitivity of red cell phenotyping for the demonstration of minor 
cell populations (at levels as low as 0.01%). The probability of 
relapse-free survival from 6 months to 4 years after BMT was 85% 
for the mixed chimeras and 65% for the complete donor chimeras. 
We conclude that in this study, mixed chimerism is not associated 
with a higher incidence of relapse. 
INTRODUCTION 
Persistence or endogenous repopulation of host-type lympho-
hematopoietic cells after allogeneic bone marrow transplantation 
(BMT) for leukemia has been considered a poor prognostic sign, 
indicating manifest or imminent r e l apse . 1 - 3 Other studies, 
however, have shown that mixed lympho-hematopoietic chimerism 
is not necessarily an indicator of an unfavorable prognosis.4 '1 2 Even 
the persistence or reappearence of the Philadelphia (Ph1) 
chromosome in patients transplanted for chronic myelogenous 
leukemia (CML) is not always associated with relapse. 9 · 1 3 - 1 8 
Using red cell phenotyping, cytogenetic analysis and restriction 
fragment length polymorphisms (RFLPs) studies, we found a high 
number of mixed chimeras and demonstrated that mixed lympho-
hematopoietic chimerism is not an indicator of imminent relapse 
in pat ients t r ansp lan ted with bone marrow, depleted of 
lymphocytes by counterflow centrlfugatlon. 
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MATERIALS AND METHODS 
Patient characteristics. Eighty-four consecutive patients were 
transplanted with lymphocyte-depleted bone marrow from a HLA-
A, -B, and -DR identical. MLC negative sibling. Informed consent 
was obtained from all recipients and donors or their guardians. 
Twenty-six died within 6 months after transplantation due to 
transplant-related complications. These 26 patients were excluded 
from further analysis. Ten additional patients were excluded since 
they relapsed within 6 months after BMT. The median age of the 
remaining 48 patients (22 males, 26 females) included was 32 
(range, 16 to 47) years. 
Indications for transplantation. The indications for transplantation 
were: acute nonlymphoblastlc leukemia (ANLL) in 14 patients (all 
in first complete remission (CRil), acute lymphoblastic leukemia 
(ALL) in nine patients (seven in CRi and two In second complete 
remission [CR2]), CML in 19 patients (15 in first chronic phase 
[CPi] and four in accelerated phase [AP])T myelodysplastic 
syndrome (MDS) In three patients (one refractory anemia [RA], one 
RA with an excess of blasts [RAEB], and 1 RAEB in transformation), 
severe aplastic anemia (SAA) in one patient, and two cases with 
lymphoblastic lymphoma (LL) in CRi. 
Condit ioning. The standard t ransplant conditioning regimen 
consisted of cyclophosphamide 60 mg/kg body weight/d (days -6 
and -5). In 22 pat ients anthracyclines were added to the 
cond i t i on ing reg imen: d a u n o r u b i c l n 26 m g / m 2 / d or 
demethoxydaunorubicin 7 mg /m 2 / d by continuous intravenous (IV) 
infusion from day -7 to -2 inclusive. All patients received 
fractionated total body irradiation (TBI) in two equal fractions of 
450 cGy each on two consecutive days (days -2 and -1) using a 18 
MV photon beam linear accelerator (Saturne, CGR, Bue, France) 
with a midline average dose-rate of 4.1 ± 0.5 cGy/min in 31 
patients, and 13.0 ± 2.0 cGy/min in 17. Lungs and eyes were 
shielded using individually adapted lead blocks. The mean 
corrected total lung-dose was 780 ± 70 cGy and 701 ± 71 cGy for 
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the patients with the lower and higher midline average dose-rate. 
respectively. 
Donor таггош. Donor marrow was depleted of 98% of lymphocytes 
by counterflow centrifugation as described by De Witte et a l . 1 9 
Virtually no residual erythrocjrtes (< IO8) were present in the final 
product. Bone marrow was infused 24 hours after completion of 
TBI. 
Immunoprophylaxis. Immunoprophylaxis postgrafting was omitted 
In one pat ient, two pat ients received methotrexate (MTX) 
according to the Seatt le r e g i m e n , 2 0 20 pat ients received 
cyclosporine A (CsA) and weekly IV injections of MTX as previously 
described. 1 9 Twenty-flve patients received CsA only, 3 mg/kg body 
weight/d by continuous IV infusion on days -1 to +14, followed by 2 
mg/kg body weight/d continuous IV on to day +21, then replaced 
by oral administration in a dose of 6 mg/kg body weight/d on to 12 
weeks after BMT, followed by a gradual tapering off with 50 mg 
every week. 
Grq/ï-uersus-host disease. The criteria for acute graft-versus-host 
disease (GVHD) described by Glucksberg eí al21 were used for 
grading severity from grade I to IV. 
Red cell phenotyping. Red cell phenotyping was performed as 
described previously. 2 2 · 2 3 In summary: at diagnosis a sample of 
patient's erythrocytes was stored in frozen state and once the 
donor was known, patient and donor were phenotyped for a 
number of red cell antigens. An antigen present on patient and 
absent on donor erythrocytes was chosen as marker for patient 
erythrocytes. An antigen present on donor and absent on patient 
erythrocytes was selected as donor marker. Blood transfusions 
were given using donor blood lacking the marker antigens. Blood 
samples were investigated 0.5, 1, 2, 3, 6, 9, and 12 months after 
BMT and annually thereafter. Depending on the technique used, 
minor subpopulations of erythrocytes can be detected at levels of 
0.01%. 
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Cytogenetic analysis. Chromosome studies were performed on 
peripheral blood cells cultured according to Arakakl and Sparkes . 2 4 
Patient and donor cells were analyzed before BMT and from the 
recipient 6 and 12 months after transplantation and once a year 
thereafter. Preparations were G-banded, 2 5 Q - b a n d e d , 2 6 and C-
b a n d e d . 2 7 When the recipient and donor were of different sex, 
identification of the Y chromosome was used. The number of 
metaphases analyzed varied from one to 100 (median 25). The 
sensitivity of this method for the demonstration of minor cell 
populations depends on the number of metaphases analyzed; 
analysis of 25 metaphases excludes 12% mixed chimerism with 
95% confidence. 2 8 
Chromosome studies were performed on unstimulated bone 
marrow samples from the recipient before BMT, 6 and 12 months 
after transplantation, and annually thereafter. The number of cells 
analyzed varied from two to 50 (median 19). Analysis of 19 
m e t a p h a s e s excludes 15% mixed chimer i sm with 9 5 % 
confidence. 2 8 
Analysis with RFLPs. Blood samples were drawn from the patient 
and donor before BMT and from the recipient 6 and 12 months 
after t ransplant and annually thereafter. Nucleated cells were 
separated by Ficoll-Isopaque centrifugation. High molecular DNA 
was extracted by standard techniques. Aliquots of 10 μg of purified 
DNA were digested to completion with EcoRI or TaqI (Boehringer 
Mannheim GmbH, Mannheim, FRG) us ing the condit ions 
recommended by the manufacturer. Completion of digestion was 
monitored by agarose gel electrophoresis after staining with 
e thidiumbromide. Digested samples were fractionated by 
electrophoresis in 0.6% or 0.8% agarose gels and transferred to 
Biotrace RP filters (Gelman Sciences Inc. Ann Arbor, MI, USA) or 
Genesereen filters (Du Pont, Boston. MA, USA) by the method of 
S o u t h e r n . 2 9 Hybridisation was carried out using the appropriate 
probes, radiolabeled by oligonucleotide priming. 3 0 The probes used 
were pAW 1 0 1 . 3 1 pDP 34,32 and pYNZ 2, pYNZ 22.1. pYNZ 23.33 
Hybridisation was visualised by exposing the membrane for a 
variable period of time at -70° С on Kodak X-Omat AR (Eastman 
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Kodak Company, Rochester, NY, USA) using intensifying screens. 
Restriction endonucleases and probes were selected to be 
informative for patient and donor cells. The sensitivity of RFLPs 
analysis for the demonstration of minor cell populations depends 
on the probes used and is in our hands about 10% of total DNA. 
De/iníííons. Mixed chlmerlsm was defined by the presence of both 
host- and donor-type hematopoietic cells in the recipient from 6 
months after BMT onward; complete donor chlmerlsm was defined 
by the presence of donor-type blood cells only in the recipient 
from 6 months after transplant onward; full host repopulation was 
defined by the presence of host-type hematopoietic cells only in 
the recipient from 6 months after BMT onward. In patients who 
relapsed, follow-up is given as the number of months between 
transplantation and relapse. In patients without relapse, follow-up 
ends on date of evaluation (July 1, 1988). 
RESULTS 
Red cell phenotyping. Forty-one patients were examined with red 
cell phenotyping at 6 months after BMT (Table 1). Twenty-one 
(51%) had mixed chimeras with 0.01% to 50% (median 0.05%) 
host-type erythrocytes. All remain In CR 9+ to 54+ (median 23+) 
months after t ransplant . Five of 18 (28%) complete donor 
chimeras relapsed, 13 (72%) remained in CR 6+ to 77+ (median 
21+) months after transplantation. One of the 2 recipients with 
only host-type erythrocytes relapsed, the second remains in CR 
37+ months after transplantation. 
Cytogenetic analysis of blood lymphocytes. Fifteen of 39 recipients 
(38%) with évaluable cytogenetic data of blood lymphocytes (Table 
1) had mixed chimeras with 4% to 73% (median 23%) host-type 
lymphocytes. Three (20%) relapsed and 12 (80%) remained In CR 
12+ to 54+ (median 20+) months after transplant. Twenty-four 
recipients (62%) were complete donor chimeras. Four (17%) 
relapsed and 20 (83%) remain in CR 9+ to 77+ (median 28+) 
months after transplantation. 
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Table 1. Number of mixed hematopoietic chimeras, complete donor chimeras, and 
patients with host-type cells only, analyzed at 6 months after transplantation with 
red cell phenotyplng, cytogenetic analysis of peripheral blood lymphocytes. 
chromosome studies of bone marrow cells, and RFLPs analysis, and number of 
relapses 
Red cell 
phenotyplng 
Cytogenetic analysis 
of blood lymphocytes 
Chromosome studies 
of bone marrow cells 
RFLPs analysis 
Total 
number* 
41(6) 
39(7) 
17(4) 
17(4) 
Mixed 
chimera 
21 (0) 
15(3) 
3(1) 
4(1) 
Complete donor 
chimera 
18(5) 
24(4) 
13(3) 
12(3) 
Full host 
repopulation 
2(1) 
0(0) 
KO) 
KO) 
'Number of patients (number of relapses) 
Cytogenetic analysis of bone marrow. Three of 17 patients (18%) 
with évaluable cytogenetic data of bone marrow cells (Table 1) had 
mixed chimeras with 9%. 17%, and 33% host-type bone marrow 
cells, respectively. One relapsed and two remain In CR 14+ and 
18+ months after BMT. Thirteen (76%) had donor-type cells only. 
Three (23%) relapsed and ten (77%) remain in CR 6+ to 45+ 
(median 15+) months after transplantation. One patient (6%) had 
host-type metaphases only. He was t ransplanted for Ph i 
chromosome positive CML. The Ph 1 chromosome reappeared 24 
months after transplantation. Until now, 37 months after BMT, he 
remains clinically and hematologically in CR 
Analysis ujffh RFLPs. Four of 17 paüents (23%) with évaluable data 
of RFLPs (Table 1) had mixed chimeras. Since the autoradiograms 
were not scanned with a spectrophotometer, we can only speculate 
about the percentage of host-type cells. One (25%) relapsed, three 
(75%) remain in CR 30+, 34+ and 40+ months after 
t ransplanta t ion. Twelve patients (71%) had complete donor 
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chimeras. Three (25%) relapsed, nine (75%) remain in CR 25+ to 
54+ (median 36+) months after transplantation. One patient (6%) 
had only host-type cells. He remains in complete clinical and 
hematological remission. 
Concordance of the different methods used. We analyzed the origin 
of hematopoietic cells at 6 months after BMT with one to four 
methods: method no. 1 In six patients. 2 in 23 patients, 3 in 14 
patients, and 4 In Ave patients. In patients examined with methods 
no. 2, 3, or 4, outcome was concordant in 48%, 2 1 % and 40%, 
respectively. Red cell phenotyplng was concordant with 
cytogenetic studies of blood lymphocytes In 12 of 32 cases (38%; 
Table 2). When we corrected for the higher sensitivity of red cell 
phenotyplng, concordance was found In 21 of 32 cases (66%; Table 
2). Red cell phenotyplng was concordant with chromosome studies 
of bone marrow cells in six of 13 cases (46%). After correction for 
the higher sensitivity of red cell phenotyplng, concordant results 
were found in 11 of 13 cases (85%). Red cell phenotyping was 
concordant with RFLPs analysis in eight of 14 cases (57%). When 
we corrected for the higher sensitivity of red cell phenotyping, 
concordant results were found in 11 of 14 cases (79%). 
Cytogenetic analysis of blood lymphocytes and bone marrow cells 
were concordant in ten of 15 cases (67%; Table 2). In four of five 
cases, discordance was due to mixed chimerism found with 
cytogenetic analysis of blood lymphocytes being complete donor 
chimeras with chromosome studies of bone marrow cells. 
Cytogenetic analysis of blood lymphocytes and studies with RFLPs 
were concordant in ten of 15 cases (67%). In three of five cases 
mixed chimerism found with cytogenetic analysis of blood 
lymphocytes was not confirmed with studies using RFLPs. 
Chromosome studies of bone marrow cells and RFLPs analysis of 
blood cells were concordant in all six cases. 
Combination of the different methods. When results of the four 
different methods were combined, mixed chimerism was observed 
in 32 of the 48 recipients (67%) at 6 months after transplantation 
(Table 3). Three mixed chimeras (9%) relapsed 12, 15, and 26 
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Table 2. Concordance between the various methods used for analysis of the origin 
of red cells, blood lymphocytes, and bone marrow cells at 6 months after 
t ransplanta t ion 
Red cell Cytogenetic Chromosome RFLPs 
phenotyplng analysis studies of analysis 
of blood bone marrow 
lymphocytes* cells 
Red cell 
phenotyplng - 12/32(38%) 6/13(46%) 8/14(57%) 
Corrected red cell 
phenotyplng* - 21/32(66%) 11/13(85%) 11/14(79%) 
Cytogenetic analysis of 
blood lymphocytes 12/32(38%) - 10/15(67%) 0/15(67%) 
Chromosome studies of 
bone marrow cells 6/13(46%) 10/15(67%) - 6/6(100%) 
RFLPs analysis 8/14(57%) 10/15(67%) 6/6(100%) 
'number of patients with concordant outcome/total number of patients analyzed 
(percentage) 
*corrected for the sensitivity for the demonstration of minor cell populations: 
0.01% for red cell phenotyplng, 12% for cytogenetic analysis of blood lymphocytes. 
15% for chromosome studies of bone marrow cells, and 10% for RFLPs analysis 
months after BMT. Twenty-nine (91%) remain In CR 9+ to 54+ 
(median 23+) months after transplantation. Nine converted to 
complete donor chimeras 9 to 24 (median 9) months after BMT 
and are in continuous CR for 9+ to 45+ (median 15+) months. 
Twenty patients remain mixed chimeras and in CR for 9+ to 54+ 
(median 24+) months after BMT. Sixteen patients (33%) were 
complete donor chimeras at 6 months after BMT (Table 3). Four 
(25%) relapsed 10. 10. 18. and 35 months after transplantation. 
Twelve patients (75%) remain in CR 6+ to 77+ (median 33+) 
months after BMT. Seven complete donor chimeras converted to 
mixed chimeras 9 to 48 (median 12) months after BMT and are In 
CR for 15+ to 77+ (median 41+) months. Three patients remain 
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Table 3. Origin of red cells, blood lymphocytes, and bone marrow cells at 
6 months posttransplant, measured with the various methods used for 
analysis* (number and occurrence of relapses and follow-up of 
patients In contlnous remission) 
No. of patients (%) 
(N = 48) 
Relapse: N (%) 
Occurrence of relapse: 
range (median)* 
Follow-up patients without 
relapse: range (median)* 
Mixed 
chimera 
32 (67) 
3(9) 
12-26 (15) 
9-54+ (23+) 
Complete donor 
chimera 
16(33) 
4(25) 
10-35 (14) 
6-77+ (33+) 
•Red cell phenotyplng. cytogenetic analysis of blood lymphocytes and bone 
marrow cells, and studies of RFLPs 
^Months after transplantation 
complete donor chimeras and in CR at 12+, 14+ and 54+ months 
after transplant, respectively. The follow-up of 2 complete donor 
chimeras is too short (6 and 7 months, respectively) for further 
evaluation. 
Hosí- and donor-type hematopoietic cells within 6 months after 
BMT. Due to the definition of mixed chimerism from 6 months 
after BMT onward, 36 patients had to be excluded from further 
analysis. Eighteen have been analyzed using red cell phenotyping: 
11 transplant-related deaths and seven patients who relapsed 
within 6 months after BMT. Eight patients (73%) and four (57%), 
respectively, had both host- and donor-type red cells before 
exclusion. The exclusion of these patients from further analysis had 
no impact on the number of mixed chimeras in this study. 
Pretransplant diagnosis and chimeric state at 6 months after BMT. 
Mixed chimerism was found in seven of 14 pat ients (50%) 
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t ransplanted for ANLL (all In CRI), in seven of nine (78%) 
transplanted for ALL (five in CRI and two In CR2). in 12 of 19 
patients (63%) transplanted for CML (11 in CP1 and one in AP). 
and in all patients with a pretransplant diagnosis of MDS, SAA, and 
LL. The three patients with mixed chimeras who relapsed, were 
transplanted for AML (one case) and CML in AP (two patients). 
Pretransplant diagnosis in the four relapsed complete donor 
chimeras was AML (two patients) and CML (two cases, both in AP). 
DISCUSSION 
In this study we assessed mixed chimerism from 6 months after 
BMT onward. Taking into consideration an erythrocyte life-span of 
120 days, it Is not possible to discriminate between surviving and 
repopula t ing host- type red cells within 120 days after 
transplantation. Although blood samples were investigated 0.5, 1, 
2, 3, 6, 9, and 12 months after BMT and annually thereafter, we 
defined mixed chimerism from 6 months after transplant onward. 
With red cell phenotyping, minor subpopulations can be detected 
at levels as low as 0.01%, making this method very sensitive for the 
demonstration of mixed chimerism. However, only the red cell 
lineage is evaluated. 
Lymphocytes may survive the pretransplant conditioning for 
months, making discrimination between surviving and repopulating 
host-type lymphocytes not possible in the early posttransplant 
period. Donor-type lymphocytes not damaged by the pretransplant 
conditioning, may be stimulated preferentially in mixed PHA-
stlmulated cultures,6 resulting in an overestlmatlon of donor-type 
lymphocytes. The sensitivity of cytogenetic analysis of blood 
lymphocytes for the demonstration of mixed chimerism, depends 
on the number of metaphases examined. To exclude 10% mixed 
chimerism with 95% confidence evaluation of at least 29 
metaphases is necessary.2 8 We examined a median number of 25 
me taphases , excluding 12% mixed chimerism with 9 5 % 
c o n f i d e n c e . 2 8 Despite the relatively low median number of 
metaphases analyzed, we found a high number of mixed chimeras 
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at 6 months after BMT. We cannot exclude, however, that surviving 
host-type lymphocytes may have biased these results. 
Compared with cytogenetic analysis of blood lymphocytes, 
chromosome studies of bone marrow cells have less methodological 
limitations: bone marrow cells are not stimulated, excluding 
potential ly preferential s t imula t ion of donor-type cells. 
Furthermore, different hematopoietic lineages are examined. A 
median number of 19 metaphases was analyzed, excluding 15% 
mixed chlmerlsm with 95% confidence. 2 8 Using this method a 
relatively low number of mixed chimeras was found at 6 months 
after transplant, which to some extent may be due to to the low 
number of metaphases examined. 
With RFLPs analysis the origin of all nucleated blood cells is 
examined. The number of mixed chimeras at 6 months after BMT 
may be influenced by surviving lymphocytes. 
The origin of hematopoietic cells at 6 m o n t h s after 
t ransp lanta t ion was examined with methods no. 1 to 4. 
Discordance in the outcome of red cell phenotyping and the other 
methods used was mainly due to the higher number of mixed 
chimeras found with red cell phenotyping, caused by the higher 
sensitivity of this method for the demonstration of minor cell 
populations. Discordance disappeared largely after correction for 
this higher sensitivity. Remaining discrepancy was caused by mixed 
chimeras, mainly found with cytogenetic analysis of blood 
lymphocytes at 6 months after BMT. In further follow-up 
discordance disappeared partly and was probably due to surviving 
host-type lymphocytes. 
Using red cell phenotyping, Branch et al4 described four 
patients with mixed chimeras in continuous CR at 375 to 662 days 
after non Τ cell depleted BMT for acute leukemia. Two of these 
four patients were also analyzed using cytogenetic analysis of blood 
lymphocytes and mixed chlmerlsm was confirmed. All four patients 
had mixed chimeras according to our definition of mixed 
chlmerlsm. Singer et al5 described a mixed chimera without 
evidence of leukemic relapse more t h a n 5 year after 
transplantation with unmanlpulated bone marrow for ALL. At 1,413 
days after BMT, mixed chlmerlsm In the myeloid cell lines was 
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confirmed by the presence of host-type colonies In bone marrow 
culture studies for granulocyte progenitor cells (CFU-C). Using 
cytogenetic studies of bone marrow cells and peripheral blood 
lymphocytes, Lawler et al 6 found recipient cells In 12 of 45 
patients (27%) who received non Τ cell depleted grafts from sex 
mismatched donors. Two remained In continuous CR at 54 and 57 
weeks after BMT. According to our definition of mixed chimerism, 
however, only three of these 12 patients had mixed chimeras and 
one remained in CR for 54+ months after BMT. With cytogenetic 
analysis, Schmitz et al 7 showed mixed chimerism in four of seven 
patients with permanent engraftment after non Τ cell depleted 
bone marrow transplantation for leukemia. Using our definition of 
mixed chimerism, however, only one of these four patients had a 
mixed chimera: in two patients mixed chimerism was not 
demonstrated from 6 months after BMT onward and the fourth 
patient relapsed within 6 months after transplantation. Knowlton 
et al8 described two pat ients with lympho-hematopoietic 
chimerism after BMT for hematologic malignancies. Using studies 
with RFLPs, In one patient host-type cells were found up to 12 
months elfter BMT without evidence of recurrence of leukemic 
cells. Yam et al9 reported on three stable mixed chimeras in 
continuous CR at 41, 53, and 58 months after non Τ cell depleted 
BMT for acute leukemia. In a prospective study of 19 patients, 
using cytogenetic studies and/or red cell phenotyping and/or 
immunoglobulin allotypes analysis, they found two transient mixed 
hematopoietic chimeras. Both remained in CR. One converted to all 
donor-type cells within 6 months after BMT; for that reason the 
patient did not have a mixed chimera according to our definition of 
mixed chimerism. Two other patients with host- and donor-type 
cells relapsed within 6 months after transplantation. In our study, 
we have excluded such patients. Yam et ál suggested that the 
prognosis for long-term remission can be good in stable mixed 
chimeras and in pat ients who convert to all donor-type 
hematopoiesis; a progressive increase in the percentage of host-
type DNA is associated with relapse. Using RFLPs studies, Bretagne 
et al10 described mixed chimerism in all of 11 recipients of Τ cell 
depleted marrow grafts transplanted for leukemia; five remained In 
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continuous CR for 9+ to 31+ months after transplantation. Four of 
these five patients were studied £ 6 months after BMT and also had 
mixed chimeras according to our definition. Petz et al11 observed 
mixed chimerism in 29 of 172 patients (17%) after non Τ cell 
depleted transplantation for hematologic malignancies; 24 (83%) 
were in continuous CR for up to 116 months after BMT. They used 
RBC phenotyping with standard techniques, RBC antibody typing 
(from 6 months after BMT onward), sex chromosomes (usually 
bone marrow specimens), immunoglobulin allotyping (from ä 100 
days after the most recent transfusion onward), and RFLPs. In 
contrast to our study, however, mixed chimerism was defined from 
14 days after BMT onward. This may have resulted in a higher 
number of mixed chimeras due to mature lympho-hematopoietic 
cells surviving the pretransplant conditioning. In a subsequent 
analysis, Petz et al 1 2 demonstrated mixed chimerism in 27 of 157 
patients (17%), transplanted with non Τ cell depleted marrow for 
leukemia and he found a survival in continuous CR of 9 3 % for 
mixed chimeras, compared with 58% for those with completely 
allogeneic hematopoiesis (p < 0.001). In our study, three of the 32 
(9%) mixed chimeras relapsed compared with four of the 16 
(25%) complete donor chimeras. Median onset of relapse was 15 
months In the mixed chimeras and 14 months in the complete 
donor chimeras, with an actuarial relapse-rate at 4 year after BMT 
of 15% in the mixed chimeras and 35% in the complete donor 
chimeras. Pretransplant diagnosis had no significant impact on 
chimeric state nor on relapse-rate in mixed chimeras and 
complete donor chimeras. The percentage of host-type red cells, 
host-type blood lymphocytes, and host-type bone marrow cells at 6 
months after BMT, did not differ between the mixed chimeras who 
relapsed and who did not. 
Severed factors may have influenced the high number of mixed 
chimeras: the lymphocyte depletion of the donor marrow, 
fractionation of the TBI,7 the relatively low midline average dose-
rate in 31 patients, 4 the immunoprophylaxis used, and the high 
sensitivity of red cell phenotyping for the demonstration of minor 
cell populations. Mixed chimerism more than 6 months after 
transplantation is rare in recipients of nonlymphocyte-depleted 
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bone marrow transplanted for leukemia. Using cytogenetic analysis, 
Hill et al34 found mixed chimerism in 56 of 96 recipients (58%) of 
unmanipulated bone marrow t ransplanted for SAA. All 96 
recipients, however, were not conditioned with TBI. Furthermore, 
mixed chimerism was defined from 14 days after BMT onward. A 
high incidence of mixed chimerism was found after transplantation 
with lymphocyte-depleted marrow grafts. Using cytogenetic studies 
Bertheas et α ϊ 3 5 found mixed chimerism in seven of 14 recipients 
(50%) of Τ cell depleted grafts compared with three of 24 
recipients (13%) of unmanipulated bone marrow. Using RFLPs, 
Bretagne et al 1 0 demonstrated mixed chimerism in all of 11 
recipients of Τ cell depleted marrow grafts compared with only 
one of 9 recipients (11%) of unmanipulated bone marrow. The 
higher Incidence of mixed chimerism in recipients of lymphocyte-
depleted bone marrow is probably caused by the removal of mature 
donor Τ lymphocytes, leading to a lower immunosuppressive effect 
on residual host h e m a t o p o i e s i s . 1 0 · 3 5 In the mixed chimeras 
residual host-type Immunocompetent cells could mitigate evolving 
acute graft-versus-host reaction after engraftment of the donor 
marrow, resulting in a reduced incidence and severity of acute 
GVHD. In recipients of unmanipulated bone marrow, persistent 
mixed chimerism may be evidence of closer tissue matching 
between recipient and donor, with, consequently, less GVHD. 3 4 
Like o t h e r s 1 0 · 1 1 · 3 4 · 3 5 we observed a low incidence of severe acute 
GVHD. Only five of 84 consecutive patients (6%) developed acute 
GVHD ä grade II. Two of the 48 patients (4%) included in this 
analysis, had severe acute GVHD > grade II: both were complete 
donor chimeras at 6 months after BMT. Due to our definition of 
mixed chimerism from 6 months after transplantation onward and 
the occurrence of acute GVHD within 3 months after BMT, we 
cannot indicate if the high incidence of mixed chimerism is the 
cause or the consequence of the low Incidence and severity of 
acute GVHD. 
The number of mixed chimeras did not differ between the two 
different midline average dose-rates of irradiation nor between 
pa t i en t s with CsA a n d / o r MTX as immunoprophylaxis . 
Furthermore, the addition of anthracyclines to the conditioning 
90 
regimen had no impact on the incidence of mixed chlmerlsm (data 
not shown). 
In conclusion, we found a high number of mixed chimeras after 
lymphocyte-depleted bone marrow transplantation associated with 
a low incidence of severe acute GVHD. Compared with complete 
donor chimeras, mixed chlmerlsm was not associated with a 
higher relapse-rate. 
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SUMMARY 
We analyzed the origin of red cells (using red cell phenotyplng), Τ 
lymphocytes (using both cytogenetic analysis and restriction 
fragment length polymorphisms studies), and of granulocytes and 
bone marrow cells (using re s t r ic t ion f ragment length 
polymorphisms studies) in 10 consecutive patients. All received 
bone marrow grafts depleted of lymphocytes using counterflow 
centrlfugatlon. Analyses were performed on identically timed 
samples from 6 months after transplantation onward. 
After correction for the higher sensitivity of red cell 
phenotyplng, results of red cell phenotyplng were concordant with 
restriction fragment length polymorphisms studies of granulocytes 
and bone marrow cells in all cases studied. Outcome of cytogenetic 
analysis and restriction fragment length polymorphisms studies of 
Τ lymphocytes were concordant in all 10 cases. Two patients had 
only mixed chlmerism in Τ lymphocytes but not in red cells nor in 
granulocytes; in one of these two patients the absence of mixed 
chlmerism was confirmed with restriction fragment length 
polymorphisms studies of bone marrow cells; bone marrow cells of 
the second patient were not available for analysis with restriction 
fragment length polymorphisms, but cytogenetic analysis of his 
bone marrow cells showed only metaphases of donor-type. 
These data show that red cell phenotyplng represents the 
hematopoietic chimeric state of granulocytes and nucleated bone 
marrow cells. Cytogenetic analysis or restriction fragment length 
polymorphisms studies of Τ lymphocytes Increases the number of 
instances of mixed chlmerism, b u t this reflects the higher 
Incidence of mixed chlmerism in the clonogenlc Τ cell population. 
These cells are less sensitive to radiochemotherapy than the 
hematopoietic stem cells and have retained the capacity for 
(limited) selfrenewal. 
INTRODUCTION 
Despite intensive pretransplant conditioning, autologous peripheral 
blood and bone marrow cells may persist after allogeneic bone 
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marrow transplantation (BMT). A recipient with both autologous 
and donor-type blood cells is defined as a mixed hematopoietic 
chimera. A high incidence of mixed chlmerism has been observed 
after t ransplantat ion with lymphocyte depleted graf ts . 1 - 4 The 
demonstration of mixed chlmerism depends on the sensitivity of 
the method used to detect this phenomenon; furthermore, 
different cell populat ions may also be investigated. Using 
cytogenetic analysis, Bertheas et al2 found a higher frequency of 
mixed chlmerism in phytohemagglutlnin (PHA) -stimulated blood 
lymphocytes than in (unstimulated) bone marrow cells. With red 
cell markers, isoenzyme analysis, immunoglobulin allotyping, and 
chromosome studies. Schouten et al3 demonstrated host-type red 
cells In 36% of cases, recipient-type myeloid cells in 7% of cases, 
host-type immunoglobulins in 100% of cases, and recipient-type 
mitotic cells in 3 of 12 (25%) évaluable patients, respectively. In a 
previous study using red cell phenotyping, cytogenetic analysis of 
PHA-stimulated blood lymphocytes, chromosome s tudies of 
unstimulated bone marrow cells, and restriction fragment length 
polymorphisms (RFLPs) of peripheral blood cells, we found mixed 
chimerlsm in 51%, 38%, 18%, and 24% of cases, respectively.4 We 
conflrmed the observation of Bertheas et al2 that mixed chlmerism 
was more frequent in PHA-stimulated blood lymphocytes than in 
(unstimulated) bone marrow cells. When assessing chimeric state, 
difference in lifetime of the population of cells under investigation 
and the sensi t iv i ty of the different popu la t ions to 
radiochemotherapy have to be taken into account. All patients had 
circulating autologous erythrocytes when red cell phenotyping was 
used to evaluate chimerlsm during the first three months after 
transplantat ion.5 Taking into consideration an erythrocyte lifetime 
of 120 days, we defined mixed chimerlsm from 6 months after 
transplantation onward.4 However, lifetime of Τ lymphocytes may 
be longer than that of red cells. This may influence the number of 
mixed chlmerism when cytogenetic analysis of PHA-stimulated 
blood cells is used for assessing chlmerism after BMT. 
In samples obtained from 10 patients consecutively attending the 
outpat ient clinic, we analyzed the origin of red cells, Τ 
lymphocytes, granulocytes and bone marrow cells using red cell 
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phenotyplng, cytogenetic analysis of Τ lymphocytes and RFLPs 
studies. Analyses were performed from 6 months after BMT onward 
on identically timed samples. All patients were transplanted in the 
same center with grafts depleted of lymphocytes using counterflow 
centrifugation. 
MATERIALS AND METHODS 
Patient characteristics. The median age of the ten patients (5 
females and 5 males) under Investigation was 32 (range 16 to 40) 
years. Bone marrow donors (5 females and 5 males) were human 
leukocyte antigen (HLA)-identical, mixed lymphocyte culture (MLC) 
negative siblings In 9 cases and an HLA-identical, MLC negative 
cousin in one case. Median age of the donors was 32 (range 18 to 
47) years. Informed consent was obtained from all patients or thelr 
guardlans. 
/ndtcations for transplantation. The indications for transplantation 
were: acute myelogenous leukemia (AML) In 2 patients, acute 
lymphoblastic leukemia (ALL) or acute undifferentiated leukemia 
(AUL) in 4 patients, chronic myelogenous leukemia (CML) in 2 
patients, and Τ lymphoblastic lymphoma and nephroblastoma, one 
case each. 
Conditioning. The patients transplanted for leukemia or lymphoma 
received s t a n d a r d p r e t r a n s p l a n t conditioning consisting of 
cyclophosphamide 60 mg/kg body weight/d (days -6 and -5) and 
fractionated total body irradiation (TBI). TBI was given in equal 
fractions of 450 cGy each on two consecutive days (day -2 and -1) 
using an 18 megavolt photon beam linear accelerator (Saturne. 
CGR, Bue, France). The midline average dose-rate was 4.2 ± 0 . 1 
cGy/mln in 5 patients and 13.1 ± 0.9 cGy/min in 4 patients. Lungs 
and eyes were shielded using individually adapted lead blocks. The 
mean corrected total lung dose was 782 ± 33 cGy/min and 715 ± 
49 cGy/min for the patients with the lower and higher midline 
average dose-rate, respectively. In 7 pat ients demethoxy-
daunorublcln was added to the conditioning regimen: 42 mg/m 2 by 
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contlnouos intravenous {Г } infusion.6 The patient transplanted for 
nephroblastoma was conditioned with polychemotherapy consisting 
of Iphosphamlde 60 mg/kg body weight/d from day -6 to day -3 
inclusive, and melphalan 180 mg/m 2 on day -2. 
Donor marrow. Donor marrow was depleted of 98% of lymphocytes 
using counterflow centrlfugation as described previously.7 Donor 
marrow was infused 24 hours after completion of TBI; the patient 
transplanted for nephroblastoma received the graft 48 hours after 
Infusion of melphalan. 
Immunoprophylaxis. Two patients received cyclosporine A (CsA) 
and methotrexate (MTX), in eight recipients immunoprophylaxis 
consisted of CsA alone as described previously.8 
Red cell phenotyping. Red cell phenotyping was performed as 
described ear l ier . 9 · 1 0 In summary: from all potential candidates for 
BMT, a blood sample was frozen at diagnosis, preferentially before 
any blood transfusion was given. If the patient had a suitable donor, 
a complete red cell phenotyping of patient and donor was 
performed. An antigen present on patient erythrocytes but not on 
donor red cells, was chosen as a patient marker; an antigen 
present on donor red cells but not on patient erythrocytes, was 
selected as a donor marker. From that moment on, only blood 
transfusions lacking the marker antigens were given. Analyses using 
the fluorescent microsphere method were performed at 0.5, 1, 2, 
3, 6, 9 and 12 months after BMT and annually thereafter. The 
sensitivity level of this method for the demonstration of minor cell 
populations is high: one positive cell per 10,000 negative cells 
(0.01%). 
Cytogenetic analysis. Peripheral blood cultures were set up from 
heparinized whole blood samples in medium 199 (Gibco, Paisley, 
Scotland, UK) supplemented with 5% (v/v) fetal calf serum (Gibco, 
Paisley, Scotland, UK) and with the addition of phytohemagglutinin 
(PHA) (Gibco. Paisley, Scotland, UK) to a final concentration of 26 
μg/ml, glutamine (2 mM), héparine (25 U/ml). penicillin (125 
100 
U/ml). and streptomycin (125 U/ml). Culture time was 96 hours at 
37 "C. Colcemld (Gibco, Paisley. Scotland, UK) to a final 
concentration of 0.2 μg/ml was added after 94 hours of incubation. 
Preparations were G-banded,11 Q-banded,1 2 or C-banded.1 3 
Karyotypes were described according to the International System 
for Human Cytogenetic Nomenclature.14 When the recipient and 
donor were of different sex, identification of the sex chromosomes 
was used. The sensitivity level of cytogenetic analysis for the 
demonstration of a minor cell population, depends on the number 
of metaphases analyzed.15 In the present study, a median number of 
31 metaphases was analyzed (range 12 to 100) excluding 10% 
mixed chimerlsm with 95% confidence. 
Isolation of subsets of blood cells. Peripheral blood samples were 
enriched for granulocytes after separation by Ficoll-Hypaque 
(Pharmacia, Uppsala, Sweden) centrifugation (density 1.077 g/ml, 
1800 rpm. 18 "С for 20 min) and lysis of the erythrocytes in the 
pellet with 0.15 M NH4CL. Purity for granulocytes in the lysed 
pellets was assessed by morphology of ä 200 cells In May-Gmnwald 
and Giemsa (MGG) stained cytosplns and varied from 95% to 99% 
(median 99%). In 5 cases, Τ lymphocytes were obtained after nylon 
wool filtration in a modification of the method described by De 
Pauw et α ϊ . 1 6 Purity for lymphocytes was demonstrated by 
morphology of £ 200 cells in MGG stained cytosplns and varied 
from 96% to 98% (median 98%). Purity for Τ lymphocytes was 
assessed after incubation with CD2 and CD3 (Ortho Diagnostic 
Systems Inc. Rarltan. NJ, USA) and after counterstalning with goat 
anti-mouse fluoresceine Isothiocyanate (GAM-FITC, American 
Qualex International. Inc. La Miranda, CA, USA) and was S 93%. 
Contamination with В lymphocytes was determined after incubation 
with CD 19 and CD20 (Coulter Immunology. Hialeah, FL. USA) and 
after counterstalning with GAM-FITC and was й 3%. In 5 patients, 
Τ lymphocytes were Isolated from peripheral blood samples with 
Immunomagnetlc beads (Dynabeads M-450 Pan-T (CD2), Dynal A.S., 
Oslo, Norway) using the conditions recommended by the 
manufacturer. This positive selection results in a Τ cell population 
containing less than 1% В lymphocytes or monocytes.1 7 
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Preparation of bone marrow samples. Bone marrow samples were 
filtered t h r o u g h 70 μ nylon filters. After Ficoll-Hypaque 
centifugation (density 1.085 g/ml, 1800 rpm. 18 CC for 20 min), 
interphase cells were collected for DNA isolation. 
RFLPs studies. DNA was extracted as described by Miller et a L 1 8 
Aliquote of 5-10 μg purified DNA were digested to completion with 
Taq I (Boehringer Mannheim, GmbH, Mannheim, FRG) using the 
conditions recommended by the manufacturer. Completion of 
digestion was monitored by agarose gel electrophoresis after 
staining with ethidiumbromide. Digested samples were fractionated 
by electrophoresis in 0.8% agarose gels and transferred to 
Genesereen filters (Du Pont, Boston, MA, USA) by the method of 
S o u t h e r n . 1 9 Hybridisation was carried out using a probe, 
radiolabeled by oligonucleotide priming. 2 0 The probe consisted of a 
mixture of the inserts of pYNZ 2, pYNZ 22.2 and pYNH 2 4 2 1 in 
equal proportions. Hybridisation was visualised by exposing the 
membrane for a variable period of time at -70 "С on Kodak X-Omat 
AR (Eastman Kodak Company, Rochester, NY, USA) using 
intensifying screens. The sensitivity of RFLPs for the demonstration 
of minor cell populations is 10% of total DNA. In mixed chimerism 
the minor cell population was not quantified. 
Definitions. Mixed chimerism was defined by the presence of both 
host-and donor-type lympho-hematopoietic cells in the recipient 
from 6 months after BMT onward; complete donor chimerism was 
defined by the presence of donor-type lympho-hematopoietic cells 
only in the recipient from 6 months after transplantation onward. 
RESULTS 
The results of red cell phenotyping, cytogenetic analysis of Τ 
lymphocytes, and RFLPs studies of Τ lymphocytes, granulocytes and 
bone marrow cells, are shown in the Table. 
With red cell phenotyping, four patients (UPN 40, 56, 60. and 92) 
appeared mixed chimeras at 6 to 36 (median 24) months after 
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Table. The origin of peripheral blood and bone marrow cells studied with red cell 
phenotyplng, RFLPs studies of granulocytes, bone marrow cells, and Τ lymphocytes, 
and cytogenetic analysis of Τ lymphocytes in 10 patients after bone marrow 
transplantation with grafts depleted of lymphocytes using counterflow 
centrlfugatlon 
UPN Dlag- Months Red cell RFLPs studies of Cytogenetic 
nosls after pheno- analysis 
BMT typing Granulo- Bone Τ lympho- of Τ Lympho­
cytes marrow cytes cytes 
36 
40 
54 
56 
60 
92 
98 
99 
103 
114 
CML 
ALL 
AML 
CML 
ALL 
MB 
ALL 
LL 
AML 
AUL 
48 
36 
36 
24 
24 
6 
12 
12 
6 
6 
fhr (100)· 
me (96) 
cdc(0) 
me (1.6) 
me (84) 
me (0.8) 
cdc(O) 
cdc(0) 
cdc(0) 
cdc(0) 
fhr 
me 
ede 
me 
me 
ede 
ede 
ede 
ede 
ede 
fhr 
me 
ede 
me 
me 
ede 
ede 
ede 
ede 
NA 
fhr 
me 
ede 
me 
me 
ede 
ede 
ede 
me 
me 
Ihr (100)· 
me (59) 
cdc(0) 
me (4) 
me (60) 
cdc(0) 
cdc(0) 
cde(0) 
me (44) 
me (83) 
•In parenthesis the percentage of autologous cells 
UPN: unique patient number, BMT: bone marrow transplantation, RCP: red cell 
phenotyplng, RFLPs: restriction fragment length polymorphisms, CML: chronic 
myelogenous leukemia, ALL: acute lymphoblastic leukemia, AML: acute 
myelogenous leukemia , NB: nephroblastoma, LL: Τ lymphoblastic lymphoma, 
AUL: acute undifferentiated leukemia, ihr: full host repopulation, me: mixed 
chimera, ede: complete donor chimera, NA: not available 
BMT. The percentage of autologous red cells varied from 0.8 to 96. 
Using RFLPs studies of granulocytes, three recipients (UPN 40, 
56, and 60) appeared mixed chimeras at 24 to 36 (median 24) 
months after BMT. 
With RFLPs studies of bone marrow cells, nine patients were 
analyzed. Bone marrow cells of UPN 114 were not available for 
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study. Three (UPN 40, 56, and 60) had mixed chlmerism at 24 to 
36 (median 24) months after BMT. 
Using cytogenetic analysis of Τ lymphocytes, mixed chimerism 
was observed In five recipients (UPN 40, 56, 60, 103, and 114) at 
6 to 36 (median 24) months after transplantation. The percentage 
of autologous Τ lymphocytes varied from 4 to 83. 
Outcome of RFLPs studies of Τ lymphocytes were identical to 
that of cytogenetic analysis of Τ lymphocytes. Combination of 
results obtained with red cell phenotyping, cytogenetic analysis of 
Τ lymphocytes, and RFLPs studies of Τ lymphocytes, granulocytes 
and bone marrow cells, showed mixed chlmerism In 6 patients 
(60%) at 6 to 36 (median 15) months after BMT; mixed chimerism 
was most frequent in Τ lymphocytes. In the mixed chimeras, the 
percentage of autologous cells varied from 0.8 to 96. All remained 
in CR at 11+ to 52+ (median 30+) months after transplantation. 
The recipient with only autologous peripheral blood and bone 
marrow cells remained clinically and hematologically in CR at 56+ 
months after BMT. 
Comparison of the different methods used. Outcome of cytogenetic 
analysis and RFLPs studies of Τ lymphocytes were concordant in all 
patients. 
Results of red cell phenotyping and analysis of Τ lymphocytes 
were discordant in three patients (UPN 92, 103, and 114); UPN 92 
had 0.8% autologous red cells, but no autologous Τ lymphocytes. 
This small percentage of autologous red cells is below the 
sensitivity level of cytogenetic analysis. UPN 103 and 114 had a 
high percentage of autologous Τ lymphocytes, but autologous red 
cells were not found. 
Both RFLPs studies of granulocytes and bone marrow cells were 
performed in 9 patients. Outcome was concordant in all cases. 
When we compared outcome of red cell phenotyping with RFLPs 
studies of granulocytes and bone marrow cells, results were 
concordant in nine out of 10 and in eight out of 9 cases, 
respectively. In one patient (UPN 92) mixed chimerism found in 
red cells was not demonstrated In granulocytes nor in bone marrow 
cells. The percentage of autologous red cells, however, was 0.8 and 
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below the sensitivity level of RFLPs studies. After correction for this 
higher sensitivity, red cell phenotyplng was concordant with RFLPs 
studies of granulocytes and bone marrow cells in all pat ients 
studied. 
Outcome of analysis of Τ lymphocytes and RFLPs studies of 
granulocytes were concordant in 8 of 10 cases. UPN 103 and 114 
had mixed chimerism of Τ lymphocytes but RFLPs of granulocytes 
showed donor-type cells only. 
DISCUSSION 
The incidence of mixed chimerism after BMT depends on the 
sensitivity of the method used, on the population of cells under 
investigation, and on the number of Τ lymphocytes in the graft.1"4 
From 6 months after transplantation onward, we assessed the 
chimeric state of red cells, Τ lymphocytes, granulocytes and bone 
marrow cells In 10 consecutive recipients of grafts depleted of 
lymphocjrtes using counterflow centrifugatlon. Red cells were 
analyzed using red cell phenotyplng with a sensitivity level for the 
demonstration of a minor red cell population of 0.01%; the origin 
of Τ lymphocytes was assessed with both cytogenetic analysis and 
RFLPs with a sensitivity level of about 10%. Granulocytes and 
nucleated bone marrow cells were Investigated using RFLPs studies 
with a sensitivity level of about 10%. In three patients, red cells as 
well as Τ lymphocjrtes, granulocytes, and bone marrow cells were of 
donor origin only. One patient (UPN 36) only had autologous red 
cells, autologous Τ lymphocytes, autologous granulocjrtes and 
autologous nucleated bone marrow cells. Donor-tjrpe red cells were 
demonstrated at 2 and 3 months after transplantation. At 6, 12, 24, 
36 and 48 months, red cell phenotyplng and cjrtogenetlc analysis of 
unstimulated bone marrow cells showed erjrthrocjrtes and bone 
marrow cells of recipient origin only. However, using cjrtogenetlc 
analysis of PHA-stimulated peripheral blood cells, donor-type Τ 
lymphocjrtes persisted in a gradually decreasing percentage and 
were still detectable at 36 months; they had disappeared at 48 
months. In this patient a low number of donor-type bone marrow 
cells may have persisted but in a percentage below the detection 
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level of cytogenetic analysis and RFLPs. In that case, however, 
donor-type red cells had to be demonstrated with the very 
sensitive technique of red cell phenotyping. It may be concluded 
that donor-type bone marrow cells have disappeared between 3 and 
6 months after transplantation; due to their long lifetime, donor-
type Τ lymphocytes have persisted for more than 30 months after 
rejection of the graft. 
In three of 6 patients with mixed chimerism (UPN 40, 56, and 
60), mixed chimerism was demonstrated in red cells as well as in 
Τ lymphocytes (both with cytogenetic analysis and RFLPs), in 
granulocytes, and in bone marrow cells. Three patients had mixed 
chimerism in one subset of cells only: UPN 92 in red cells and UPN 
103 and 114 in Τ lymphocytes. The percentage of autologous red 
cells in UPN 92 was 0.8 and below the detection level of the other 
methods. Since red cell phenotyping was performed at 6 months 
after transplantation, and taking into consideration an erythrocyte 
lifetime of 120 days, these autologous red cells must originate from 
hematopoietic cells surviving pretransplant regimen; due to the 
relatively low sensitivity level of RFLPs, host-type hematopoietic 
cells were not demonstrated in bone marrow cells. UPN 103 and 
114 had mixed chimerism in Τ lymphocytes only. Despite the high 
percentage of autologous Τ lymphocytes, mixed chimerism was not 
seen in red cells, granulocytes or bone marrow cells (In UPN 114, 
bone marrow cells were not available for RFLPs studies, b u t 
cytogenetic analysis of 15 metaphases of bone marrow cells showed 
donor-type cells only). If autologous hematopoietic bone marrow 
cells were still present but in a percentage below the detection 
level of RFLPs. autologous red cells should have been found. Since 
no autologous red cells were demonstrated, the autologous Τ 
lymphocytes must originate from clonogeneic Τ lymphocytes which 
have survived pretransplant conditioning regimen. This Is in 
agreement with the relatively low sensitivity of Τ cells to 
r a d i a t i o n . 2 2 If these patients do not relapse, Τ lymphocytes may 
disappear in further follow-up, assuming limited selfrenewal 
capacity of clonogenic lymphoid cells. 
In conclusion: when assessing chimerism of peripheral blood 
cells after transplantation with lymphocyte depleted grafts, lifetime 
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of pretransplant regimen surviving peripheral blood cells has to be 
taken into account : Τ lymphocytes which have survived 
pretransplant conditioning regimen, may increase the number of 
mixed chimeras. Red cell phenotyplng was concordant with RFLPs 
studies of both granulocytes and bone marrow cells, t h u s red cell 
phenotyplng may represent chimerlsm of nucleated bone marrow 
cells. Studies on mixed chimerlsm after BMT may be easier to 
interpret if more precise definitions will be used. Hematopoietic 
mixed chimerlsm should be restricted to those mixed chimeras in 
which the autologous cells clearly originate from autologous 
hematopoietic stem cells with self-renewal capacity. If mixed 
chimerlsm only occurs in the lymphoid population, it may be more 
appropriate to define this state as mixed lymphoid chimerlsm. 
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SUMMARY 
We performed chromosome studies on 121 paired samples of 
phytohaemagglutinin-stimulated blood and unst imulated bone 
marrow cells from 57 recipients of lymphocyte depleted grafts 
using counterflow centrifugation. The paired samples were drawn 
simultaneously 6 to 108 months after t ransplantat ion. The 
Incidence of mixed chimerism was higher in blood than in bone 
marrow cells, both in patients who relapsed and in patients in 
continuous complete remission. The higher number of mixed 
lymphoid chimeras is caused by autologous Τ lymphocytes which 
have survived conditioning regimen and/or by donor lymphocytes 
which persisted after disappearance of the marrow graft. 
The type of blood and bone marrow chimerism had no significant 
impact on the incidence of chronic graft-versus-host disease 
(GVHD) but the overall Incidence of chronic GVHD was too low to 
allow an accurate assessment. 
Cytogenetic analysis is a useful method for assessing chimerism 
after bone marrow transplantation. Apart from its limited sensitivity 
for the demonstration of a minor cell population, discrepancies 
between chromosome studies of blood cells (lymphoid chimerism) 
and bone marrow cells (myeloid/erythrold chimerism) have to be 
taken Into consideration. 
INTRODUCTION 
Cytogenetic analysis of blood and bone marrow cells is used to 
assess chimerism after allogeneic bone marrow transplantation 
(BMT). 1 " 1 9 Both in recipients of untreated grafts and in recipients 
of Τ cell depleted marrow the incidence of mixed chimerism was 
higher in blood than In bone marrow m e t a p h a s e s . 1 5 · 1 6 This 
discrepancy is caused by the different hematopoietic cell lineages 
which are analysed with chromosome studies of blood and bone 
marrow cells, respectively. With chromosome s t u d i e s of 
unstimulated bone marrow cells myeloid and erythrold cells are 
analysed and lymphoid cells are studied with cytogenetic analysis of 
phytohemagglutlnln (PHA)-stimulated blood cells. 
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In order to a s ses s the degree of discordance between 
chromosome studies of blood and bone marrow cells in recipients 
of Τ cell depleted grafts using counterflow centrifugation, we 
extended our earlier observations 1 6 to the analysis of 121 paired 
blood and bone marrow samples of 57 patients. Chromosomal 
abnormalities in autologous blood and bone marrow cells and causes 
of discordant outcome are discussed. 
MATERIALS AND METHODS 
Paired blood and bone marrow samples were available in 57 
patients (34 males and 23 females) transplanted between May 1982 
and September 1989. Bone marrow donors were HLA -A, -B, and 
-DR identical, mixed lymphocyte culture negative siblings. Median 
age of the patients was 32 years (range 16-47). The indications for 
transplantation were acute myeloid leukaemia (AML, 13 patients), 
acute lymphoblastic leukaemia (ALL, 16 patients), chronic myeloid 
leukaemia (CML, 20 patients), myelodysplastic syndrome (four 
patients), and others (four patients). Median age of the marrow 
donors (39 males and 18 females) was 32 years (range 13-49). 
Informed consent was obtained from all patients and donors or 
their guardians. 
T r a n s p l a n t procedure . The s tandard conditioning regimen 
consisted of cyclophosphamide 60 mg/kg on days -6 and -5, and of 
fractionated total body irradiation (TBI) in two equal fractions of 4.5 
Gy each on days -2 and -1, using an 18 MV photon beam linear 
accelerator (Saturne. CGR, Bue, France). The midline average dose-
rate was 44 ± 3 mGy/min in 28 patients and 133 ± 16 mGy/min in 
29 patients. Lungs and eyes were shielded using individually 
adapted lead blocks. The average lung dose was 7.8 + 0.4 Gy and 7.0 
± 0.7 Gy for the patients with the lower and higher midline average 
dose-rate, respectively. In 33 patients anthracyclines were added to 
the s tandard regimen, either daunorubicin 156 m g / m 2 or 
demethoxydaunorubicin 42 mg/m 2 given by continuous Intravenous 
Infusion. Twenty-three p a t i e n t s were condit ioned with 
cyclophosphamide and TBI at the lower midline average dose-rate 
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but without the addition of anthracycllnes (conditioning regimen 1) 
and 28 were conditioned with cyclophosphamide and TBI at the 
higher midline average dose-rate and with the addition of 
anthracyclines (conditioning regimen 2). Five patients received 
cyclophosphamide and TBI at the lower midline average dose-rate 
and with the addition of anthracyclines, one patient was 
conditioned with cyclophosphamide and TBI at the higher midline 
average dose-rate but without the addition of anthracyclines. 
On day 0 the patients received donor marrow depleted of 
lymphocytes using density gradient centrifugation followed by 
counterflow centrifugation.20 
Immunoprophylcuds. Immunoprophylaxls postgraftlng consisted of 
methotrexate (MTX) in two patients,2 1 both MTX and cyclosporine 
A (CsA) in 17 patients,22 and CsA only in 38 patients.22 
Cytogenetic analysis. Peripheral blood samples from the recipient 
and the marrow donor were analysed before BMT. Blood and bone 
marrow samples of the recipient were analysed at 6 and 12 months 
after transplantation and annually thereafter. Each pair of blood and 
bone marrow samples was collected on the same day. Peripheral 
blood cells were cultured from heparlnized whole blood samples in 
RPMI 1640 medium (Gibco. Paisley, Scotland. UK) supplemented 
with 10% fetal calf serum (Gibco. Paisley. Scotland, UK), glutamlne 
(2 nM). penicillin (125 U/ml) and streptomycin (125 U/ml). After 
addition of PHA (Gibco. Paisley, Scotland. UK) to a final 
concentration of 26 μg/ml, blood cells were Incubated for 92 hours 
at 37° С After 90 hours, colcemld (Gibco, Paisley. Scotland, UK) 
was added to a final concentration of 0.2 Hg/ml. Then the cells 
were washed and resuspended in 0.075 mol/1 KCL for 20 minutes 
at 37° C. Finally, chromosome slides were prepared after several 
rounds of fixation in 1:3 glacial acetic acid-methanol solution. 
Preparations were GTG-banded.23 QFQ-banded,24 and/or CBG-
banded.2 5 In 32 cases the recipient and donor were of different sex 
and Identification of the sex chromosomes was used. Autosomal 
heteromorphisms on chromosomes 1, 3, 4, 9, 13, 14, 15, 21, and 
22 were used to differentiate between donor and recipient In 24 
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patients with sex-matched donors. In five of these recipient-donor 
pairs, differentiation was based on heteromorphism on two or more 
different autosomes. One sex-matched donor had a paracentric 
inversion of the short arm of chromosome 7 which was used for 
differentiation. Karyotypes were described according to the 
standard international nomenclature (ISCN).26The mean number of 
blood metaphases analysed was 26 (range 3-100). This average 
number allows the detection of a level of 11% mosaicism with 95% 
confidence.27 
Bone marrow cells were prepared directly for cytogenetic 
analysis or cultured for 24 hours in RPMI 1640 medium without 
PHA stimulation. Further preparation and banding techniques and 
describing of karyotypes were performed as mentioned above. The 
mean number of bone marrow cells analysed was 18 (range 5-50). 
This average number allows the detection of a level of 16% 
mosaicism with 95% confidence.27 
Síaítstical analysis. For statistical analysis the Fisher's exact test was 
used. Calculations were made using the SAS programme (SAS 
Institute Inc., Сагу, NC, USA). Ρ values < 0.05 were considered 
significant. 
De/íní í ions. Chimerism was defined in blood cells (lymphoid 
chimerism) and bone marrow cells (myeloid/erythroid chimerism). 
Mixed chimerism was defined as the presence of both host and 
donor-type metaphases; complete donor chimerism was defined by 
the presence of 100% donor metaphases; full host repopulation was 
defined by the presence of 100% autologous metaphases. Relapse 
was defined as the reappearance of any clinical, cytogenetic or 
hematological feature of the original disease. 
RESULTS 
Overall incidence of mixed chimerism in paired blood and bone 
marrow samples. Mixed chimeras were found in 64 of 121 (53%) 
blood semipiés and in 34 of 121 (28%) bone marrow samples (p < 
0.05, Table 1). 
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Table 1. Number (%) of mixed chimeras in paired blood and bone marrow 
samples 
Number (%) of mixed chimeras 
In blood ρ In bone 
cells value marrow cells 
All patients (121 samples) 64 (53) < 0.05 34 (28) 
Patients conditioned 
with regimen 1 (50 samples) 27 (54) < 0.05 16 (32) 
Patients conditioned 
with regimen 2 (58 samples) 30 (52) < 0.05 15 (26) 
In patients conditioned with regimen 1, mixed chimeras were 
found in 27 of 50 (54%) blood samples and in 16 of 50 (32%) bone 
marrow samples (p < 0.05) In the patients conditioned with the 
intensified regimen (regimen 2) these figures were 30 of 58 (52%) 
and 15 of 58 (26%) (p < 0.05). respectively. 
In pat ients conditioned with the intensified regimen, the 
incidence of mixed chimeras in blood cells was lower than in 
patients conditioned with regimen 1 b u t the difference was not 
statistically significant. The same was true for the incidence of 
mixed chimeras in bone marrow cells. 
Chromosome studies in blood and bone таггош cells of patients 
who relapsed. Sixteen of the 57 patients (28%) relapsed. Relapse 
occurred at 6 to 60 (median 24) months after BMT. Indications for 
transplantation were CML in 12 cases (eight in first chronic phase 
and four in accelerated phase), and one case each of AML in first 
complete remission (CRI), ALL in CRI. ALL in third complete 
remission (CR3), and refractory anemia with an excess of blasts 
(RAEB) in CRI. At diagnosis and immediately before conditioning. 
bone marrow cells of the patients transplanted for CML were 
Philadelphia (Ph1) chromosome positive. In these patients relapse 
occurred with the reappearance of the P h 1 chromosome in bone 
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marrow cells and in one patient the Ph1 chromosome was also 
found in autologous lymphocytes. Bone marrow cells of the patient 
transplanted for ALL-CR1 showed polyploidy at diagnosis which had 
disappeared immediately before conditioning for transplantation. 
When he relapsed autologous bone marrow cells showed del (13q) 
and multiple non-clonal chromosomal abnormalities. The other 
three patients had no chromosomal abnormalities at diagnosis or 
immediately before conditioning for transplantation. When relapse 
occurred, the patient transplanted for ALL-CR3 had pseudotriploidy 
in autologous bone marrow cells and bone marrow cells of the 
patient transplanted for RAEB-CR1 showed multiple non-clonal 
chromosomal abnormalities. Bone marrow cells of the patient 
t ransplanted for AML-CRI were not available for cytogenetic 
analysis after relapse had occurred. 
Results of chromosome studies on 38 paired blood and bone 
marrow samples of the 16 patients who relapsed are presented in 
two sections: the first section presents chromosome studies on 
blood and bone marrow cells before relapse occurred and the 
following section presents chromosome studies on blood and bone 
marrow cells from occurrence of relapse onward. 
Chromosome studies on blood and bone marrow cells of patients in 
remission with subsequent relapse. Seventeen paired samples were 
studied before relapse occurred (Table 2). The Interval between the 
last cytogenetic analysis performed in the patient being in 
remission and the first chromosome study when the patient had an 
overt relapse, varied from 6 to 18 (median 12) months. Mixed 
chimeras were found in 10 of 17 blood samples (59%) and in four 
of 17 bone marrow samples (24%) (p > 0.05). In all but three 
mixed lymphoid chimeras autologous cells had multiple non-clonal 
but no clonal chromosomal abnormalities. Autologous cells of three 
of the four bone marrow mixed chimeras had chromosomal 
abnormalities. These were non-clonal in two cases (ALL and CML), 
and clonal in the patient transplanted for RAEB: he showed del 
(12p) in four of eight autologous male bone marrow cells. The 16 
female donor cells were without abnormalities. 
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Complete donor chimeras were found in 7 of 17 blood samples 
(41%) and in 12 of 17 bone marrow samples (71%) (p > 0.05, 
Table 2). 
Table 2. Chlmerlsm In blood and bone marrow (BM) cells of patients in remission 
with subsequent relapse (Group 1). of patients with relapse (Group 2), and of patients 
in continuous complete remission (Group 3) 
Number (%) of samples with 
Mixed 
chimeras 
m in 
Blood BM 
Complete donor 
chimeras 
I n in 
Blood BM 
Full host 
repopulation 
I n In 
Blood BM 
Group 1 
(17 samples) 
Group 2 
(19 samples) 
GroupS 
(85 samples) 
10(59) 4(24) 7(41) 12(71) 0(0) 1(5) 
16(84)# 5(26)* 2(11) 0(0) 1 (5)* 14 (74)# 
38(45) 25(29) 47(55) 60(71) 0(0) 0(0) 
#p<0.05 
Only autologous cells were found in none of 17 blood samples and 
in one of 17 bone marrow samples (5%) (Table 2). The autologous 
bone marrow cells showed multiple but non-clonal chromosomal 
abnormalities. 
Chromosome studies on blood and bone таггош cells of patients 
with relapse. Nineteen paired samples were studied from diagnosis 
of relapse onward (Table 2). Eighteen were from pat ient s 
transplanted for CML, one paired sample was from the patient 
transplanted for RAEB (the patient who relapsed from AML died 
without further cytogenetic follow-up, and in the two patients with 
a relapse of ALL only bone marrow cells were analysed). Mixed 
chimeras were found in 16 of 19 blood samples (84%) and in 5 of 
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19 bone marrow samples (26%) (ρ < 0.05). Eleven of 16 mixed 
lymphoid chimeras (69%) had chromosomal abnormalities in 
autologous cells. These were multiple but non-clonal in 10 cases 
and clonal in one case showing the P h 1 chromosome in two 
autologous cells. The autologous bone marrow cells of the Ave bone 
marrow mixed chimeras were without abnormalities in the patient 
transplanted for RAEB-CR1. The del (12p) which was found in four 
of 8 autologous bone marrow metaphases of this patient before he 
relapsed, had disappeared and could not be demonstrated in 12 
autologous bone marrow metaphases. The other four patients were 
t ransplanted for CML and all had the P h 1 chromosome in 
autologous bone marrow cells. In one case the Ph 1 chromosome was 
associated with a clonal abnormality [t(l;2)] and in another case 
multiple but non-clonal chromosomal abnormalities were found. 
Two of 19 samples (11%) had only donor lymphoid cells. 
Complete donor chimeras were not observed in any of the bone 
marrow samples. 
One hundred percent autologous cells were found in one of 19 
blood samples (5%) and in 14 of 19 bone marrow samples (74%) (p 
< 0.05. Table 2). In the patients with 100% autologous blood cells 
multiple non-clonal but no clonal chromosomal abnormalities were 
found. In all cases with 100% autologous bone marrow cells the Ph 1 
chromosome had reappeared and in almost all patients the P h 1 
chromosome was found in all autologous metaphases. In all but 
three cases bone marrow cells with the Ph 1 chromosome showed 
addi t iona l mult iple non-clonal a n d clonal chromosomal 
abnormalities like t(l;10), t(2;6) together with del (7q). t ( l l ;15) . 
t(l;10), inv (17q), del (Iq). del (7q), del (5q), 12q+ and t(12;22). 
Chromosome studies in blood and bone marrow cells of patients in 
continuous complete remission. Forty-one of the 57 recipients 
(72%) did not relapse. Time interval between the last cytogenetic 
analysis and the end of follow-up was 2 to 13 (median 8) months. 
The patients who did not relapse were transplanted for AML in CRI 
(13 cases). ALL in CRI (11 cases), ALL > CRI (three cases), CML in 
CP1 (eight patients) and others in six cases. Both at diagnosis and 
immediately before conditioning for transplantation cytogenetic 
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analysis of bone marrow cells was performed In 28 patients (68%) 
transplanted for AML (N=8), ALL (N=9), CML (N=8), and others 
(N=3). At diagnosis clonal chromosomal abnormalities were found 
in 17 of 28 patients (61%) transplanted for AML (N=5. three had 
t(8;21) and two had trisomy 8). ALL [N=4, one had the Ph 1 
chromosome, one had t(l;12), one had hyperploidy. and the fourth 
patient had del (7p). del (9p). and del (12p)], CML (N=7, all were 
Ph 1 chromosome positive], and one case with refractory anaemia 
(RA) with del (13q). Immediately before condit ioning for 
t ransplantat ion the Ph 1 chromosome was still present In the 
patients with CML, but chromosomal abnormalities had disappeared 
in all other patients, except the patient transplanted for RA. This 
patient was not treated before conditioning. 
Follow-up varied from 29 to 116 (median 58) months . The 
number of paired blood and bone marrow samples analysed was 85 
(Table 2). Mixed chimeras were found in 38 of 85 blood samples 
(45%) and in 25 of 85 bone marrow cells (29%) (p > 0.05). In 83% 
and 67% of the blood and bone marrow mixed chimaeras, 
respectively, autologous cells had non-clonal chromosomal 
abnormalities. Autologous bone marrow cells with a clonal 
chromosomal abnormality were found in only one patient (UPN 4). 
She was transplanted for t(8;21)-positive AML. At 60 and 72 
months she had mixed chimerism in bone marrow cells with 
autologous cells showing del (13q) and multiple non-clonal 
abnormalities but no t(8;21). At 84 and 96 months chromosome 
studies were not performed on bone marrow cells bu t at 108 
months bone marrow cells showed mixed chimerism with 
autologous cells still showing del (13q) and multiple non-clonal 
abnormalities but no t(8;21). Until now, more than 108 months 
after transplantation this patient remains in complete clinical, 
cytogenetic, and hematological remission of the original disease. 
Probably, this patient has developed a myelodysplastlc syndrome. 
Complete donor lymphoid chimeras were found in 47 of 85 cases 
(55%) and complete donor bone marrow chimaeras in 60 of 85 
samples (71%) (p > 0.05. Table 2). 
None of the blood or bone marrow samples had only autologous 
cells. 
121 
Incidence of GVHD. Since chromosome s t u d i e s were not 
performed within 6 months after transplantation we could not 
assess the impact of chimerlsm on the incidence of acute GVHD. 
Eleven of 57 recipients (19%) had chronic GVHD with an onset 
from 3 to 6 (median 5) months after BMT. Cytogenetic analysis of 
blood cells at 6 months Elfter BMT was performed In 50 patients. 
Three of 21 (14%) recipients with mixed lymphoid chimeras had 
chronic GVHD compared to six of 29 (21%) patients with 100% 
donor blood cells (p > 0.05, Table 3). 
Table 3. Chimerlsm In blood cells of patients with chronic GVHD and 
of patients without chronic GVHD at 6 months after transplantation 
mixed ρ complete donor 
chimeras value chimeras 
(N=21) (N=29) 
Patients with 
chronic GVHD 3(14%) >0.05 6(21%) 
Patients without 
chronic GVHD 18(86%) >0.05 23(79%) 
Chromosome studies of bone marrow cells at 6 months showed 
mixed chimeras or complete donor chimeras in 32 patients. None 
of six bone marrow mixed chimeras and 9 of 26 (35%) patients 
with 100% donor bone marrow cells had chronic GVHD (p > 0.05, 
Table 4). 
DISCUSSION 
Cytogenetic analysis is a useful method to assess chimerlsm after 
allogeneic BMT. It must be emphasized that with chromosome 
studies of PHA-stimulated blood cells only Τ lymphocytes are 
analysed (lymphoid chimerlsm) and with cytogenetics of 
unstimulated bone marrow cells myeloid and erythroid cells are 
studied (myeloid/erythroid chimerlsm). The difference in cell 
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Table 4. Chlmerism in bone marrow cells of patients with chronic 
GVHD and of patients without chronic GVHD at 6 months after 
transplantation 
mixed ρ complete donor 
chimeras value chimeras 
(N=6) (N=26) 
Patients with 
chronic GVHD 0(0%) >0.05 9(35%) 
Patients without 
chronic GVHD 6(100%) >0.05 17(65%) 
lineages under Investigation may result In discordant outcome of 
chromosome studies on paired blood and bone marrow cells. 
Furthermore, the number of metaphases analysed has to be taken 
into consideration since the sensitivity of cytogenetics for the 
demonstration of a minor cell population depends on the number of 
metaphases analysed. We analysed an average number of blood and 
bone marrow metaphases of 26 and 18, respectively, allowing the 
detection of a level of 11% and 16% mosaicism with 9 5 % 
confidence, respectively.2 7 This is far below the sensitivity level of 
red cell phenotyping using the fluorescent microsphere assay 2 8 and 
molecular t e c h n i q u e s . 2 9 " 3 1 In this study, the significant higher 
number of mixed lymphoid chimeras was not caused by the higher 
average number of blood metaphases analysed: when we compared 
pairs of blood and bone marrow samples In which the number of 
blood metaphases was equal to or lower than that of bone marrow 
metaphases the difference between mixed lymphoid and bone 
marrow chimeras remained significant (17 of 27 (63%) versus 
seven of 27 (26%), respectively, (p < 0.05). 
Significant more blood than bone marrow mixed chimeras were 
found In patients with a relapse. The Incidence of mixed chlmerism 
was higher in blood than In bone marrow cells of patients in 
remission with subsequent relapse b u t the difference was not 
significant. The same was true for patients in continuous complete 
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remission. After adding up the numbers of blood and bone marrow 
mixed chimeras, respectively, of these two categories of patients, 
significant more blood than bone marrow mixed chimeras were 
found (48 of 102 (47%) versus 29 of 102 (28%), ρ < 0.05). 
We confirmed the observation of Bertheas et α ϊ . 1 5 · 3 2 Using 
cytogenetics, they observed more mixed lymphoid chimeras than 
bone marrow mixed chimeras, both in recipients of Τ cell depleted 
and untreated grafts. 
In the first year(s) after BMT the higher number of mixed 
chimerlsm in blood cells can be explained by the persistence of 
autologous Τ lymphocytes which have survived pretransplant 
conditioning r e g i m e n . 3 3 · 3 4 These Τ lymphocytes are expected to 
disappear during longer follow-up. 1 9 One patient had mixed 
lymphoid chimerism but only donor bone marrow metaphases at 6, 
12 and 24 months . The percentage of autologous lymphoid 
metaphases was 30, 4, and 4, respectively. At 36 months after BMT 
only donor metaphases were found in both blood and bone marrow 
cells. 
On the other hand, in patients who relapse or reject the graft 
circulating donor Τ lymphocytes may persist after disappearance of 
the g r a f t . 5 · 1 9 · 3 5 During longer follow-up host lymphoid cells may 
reappear causing mixed lymphoid chimerism in patients with only 
autologous bone marrow cells. Ultimately, donor-type lymphoid 
cells will disappear leading to 100% autologous cells in both blood 
and bone marrow. This was observed in a patient transplanted for 
CML-CP1. Within 6 months after transplantation he rejected the 
graft and from 6 to 48 months after transplantation cytogenetic 
analysis of bone marrow cells showed only autologous cells with 
reappearance of the P h 1 chromosome. However, at 6, 12, 24 and 
36 months blood metaphases showed mixed chimerism with 42%, 
5%, 23%, and 4% donor lymphocytes, respectively. Lymphoid cells 
of donor origin had disappeared completely at 48 months. 
The Incidence of mixed chimerism in both blood and bone 
marrow cells did not differ significantly between patients in 
remission with subsequent relapse and patients in continuous 
complete remission. In this larger population we thus confirmed 
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our earlier observations that mixed chimerism is not associated 
with a higher incidence of relapse. 1 6 
In most cases autologous lymphoid cells showed multiple non-
clonal chromosomal abnormalities probably as a consequence of 
radiation d a m a g e . 5 · 1 2 · 1 7 P h 1 chromosome positive autologous blood 
cells were found in only one case. This patient had a cytogenetic 
relapse of his CML at three years after BMT. All bone marrow cells 
were male and P h 1 chromosome positive. Of the 35 blood cells 
analysed, two were male and P h 1 chromosome positive, the 
remaining 33 cells were P h 1 negative and from his female donor. 
Peripheral blood smears showed a low percentage of Immature 
cells ( 1 % metamyelocytes and 4% rods). We cannot exclude that 
the two autologous P h 1 positive blood cells were of myeloid origin 
although the great majority of blood cells after 92 h o u r s of 
incubation with PHA are Τ lymphocytes. Although Τ lymphocytes 
usually are not involved in the leukemic p r o c e s s 5 · 3 6 we confirm the 
observation of Schmitz et al6 and Alimena et al17 who observed 
P h 1 positive cells in PHA stimulated cultures of blood cells. Two of 
the four patients described by Alimena et al17 were in complete 
remission with 100% donor bone marrow cells, the other two 
patients had bone marrow relapse but normal leukocyte numbers 
and normal differentials. The authors did not rule out a lymphoid 
origin of these P h 1 positive blood cells but hypothesized that these 
cells were morphologically unidentifiable leukemic stem cells 
recirculating from bone marrow or other sites. 
Also autologous bone marrow cells showed multiple non-clonal 
chromosomal abnormalities in most instances. After relapse had 
occurred additional clonal abnormalities were f o u n d . 5 · 1 2 · 1 7 · 1 9 One 
patient without cytogenetic or hematological relapse of the original 
disease, developed a clonal chromosomal abnormality in autologous 
bone marrow cells at 5 years after transplantation probably as a sign 
of a myelodysplastic syndrome. 
The Incidence of chronic GVHD was higher in patients with 
100% donor lymphoid cells t h a n in recipients with mixed 
lymphoid chimerism although the difference was not statistically 
significant. We thus confirmed the observation of Bertheas et o L 3 3 
None of six pat ients with bone marrow mixed chimeras had 
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chronic GVHD in contrast to nine of 26 with 100% donor bone 
marrow cells. Using red blood cell markers and cytogenetic studies 
of bone marrow cells, Frassoni et al found a significant higher score 
of chronic GVHD in patients with complete chimerism. 1 8 They 
suggested t h a t mixed chimerism may be involved in the 
development of tolerance but on the other hand, they do not rule 
out that mixed chimerism could be the consequence of a low GVHD 
activity. In the present study, mixed chimerism was associated with 
less chronic GVHD but we can only speculate on the impact of 
blood versus bone marrow mixed chimerism on the occurrence of 
chronic GVHD. 
In conclusion: in patients who relapsed, both before relapse 
occurred and after relapse had occurred, and in patients who did 
not relapse, the incidence of mixed chimerism was higher in blood 
than in bone marrow cells. This is caused by conditioning regimen 
surviving Τ lymphocytes and/or by persisting donor lymphocytes 
after disappearance of the marrow graft. Less mixed chimeras were 
observed in blood and bone marrow samples of the patients 
conditioned with the intensified regimen although the difference 
was not statistically significant. The incidence of chronic GVHD was 
higher in patients with only donor lymphoid cells although this 
difference was not statistical significant and the same was true for 
patients with 100% donor bone marrow cells. 
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SUMMARY 
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SUMMARY 
In chapter 1 the origin of the term chimera is explained and a 
definition of chimerism is given. 
Chapter 2 describes the history of bone marrow transplantation. In 
the fifties, it was shown that animals could be protected against 
otherwise lethal irradiation by covering of the spleen with lead or 
by infusion of donor bone marrow. It became evident that this effect 
was not caused by an humoral factor b u t by colonization of the 
recipient's bone cavity with hematopoietic cells of the donor 
marrow. However, success of bone marrow transplantat ion in 
leukemia was disappointing. Recipients of genetically identical 
grafts died from relapsed leukemia. Most recipients of genetically 
non-identical grafts died ultimately from secondary syndrome 
(graft-versus-host disease, GVHD), but without signs of leukemia. It 
was recognized that GVHD was associated with a graft-versus-
leukemia effect. The recognition of the major histocompatibility 
complex In the sixties and seventies contributed greatly to 
prevention of GVHD and t h u s to success of bone marrow 
transplantat ion. However, GVHD remained one of the major 
obstacles. Τ cell depletion of the marrow graft effectively prevented 
GVHD, but was associated with a higher relapse-rate. Reduction of 
relapse-rate in recipients of Τ cell depleted grafts h a s been 
achieved by intensification of the conditioning regimen. 
Allogeneic bone marrow transplantation has become a worldwide 
accepted t r e a t m e n t modality for several m a l i g n a n t a n d 
nonmallgnant diseases. The number of patients that can be cured by 
allogeneic bone marrow transplantation h a s increased by the 
creation of national and international bone marrow donor registries. 
Results of the first eighty consecutive patients transplanted for 
acute leukemia and chronic myelogenous leukemia (CML) at the 
University Hospital Nijmegen are given in chapter 3. All patients 
received human leukocyte antigen (HLA)-identical sibling-marrow. 
In all cases, donor marrow was depleted of lymphocytes using 
counterflow centrifugatlon. Median age of the recipients was 31 
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years. Pretransplant conditioning consisted of cyclophosphamide 
and fractionated total body irradiation. In 43 patients, cytosine-
arabinoside or anthracyclines were added to the conditioning 
regimen. Graft failure occurred in 4 of 77 évaluable patients (5%). 
Both the probability of acute GVHD grade 2 or more and the 
probability of extensive chronic GVHD was low (15% and 12%, 
respectively). The projected 3-year probability of relapse was 30%, 
35%, and 38% after transplantation for acute myeloid leukemia 
(AML) in first complete remission (CRI), acute lymphoblastic 
leukemia (ALL) in CRI, and CML In first chronic phase (CPl), 
respectively. The projected 3-year probability of leukemia-free 
survival was 56%, 42%, and 49% in patients transplanted for AML 
in CRI, ALL in CRI, and CML in CPl, respecUvely. Probabilities of 
relapse, survival and leukemia-free survival in AML-CR1 and ALL-
CR1 were comparable with those reported in the literature on 
recipients of untreated grafts. In patients transplanted for CML-
CP1, probability of relapse was higher and probability of leukemia-
free survival was lower than in recipients of untreated grafts. In 
transplants for leukemia in CRI and CPl, preparative regimen was 
not associated significantly with the probability of acute GVHD 
grade 2 or more, extensive chronic GVHD, relapse, survived, or 
leukemia-free survival. The high number of mixed chimeras was 
indicated. 
We conclude that in bone marrow transplantation for leukemia, 
counterflow centrifugatlon is a useful technique for the prevention 
of GVHD. In our patients transplanted for leukemia In CRI and CPl, 
probability of survival and leukemia-free survival can compete with 
that reported in studies from the literature on recipients of 
untreated marrow. Further efforts have to be made to reduce 
relapse-rate, particularly in CML transplants. 
In chapter 4 we report on the high number of mixed chimeras in 
recipients of marrow grafts depleted of 98% of lymphocytes using 
counterflow centrifugatlon. Marrow donors were HLA-A, -B, and 
-DR identical, mixed lymphocyte culture negative siblings. Methods 
used for the demonstration of mixed chimeras were red cell 
phenotyping, cytogenetic analys is of blood lymphocytes. 
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chromosome studies of bone marrow cells, and restriction 
fragment length polymorphisms (RFLPs) studies of peripheral blood 
cells. Thirty-two of 48 recipients (67%) appeared to be mixed 
chimeras at 6 months after transplantation. The high number of 
mixed chimeras was probably a result of lymphocyte depletion of 
the marrow graft and the high sensitivity of red cell phenotyping 
for the demonstration of minor cell populations (at levels as low as 
0.01%). The probability of relapse-free survival from 6 months to 4 
years after BMT was 85% for the mixed chimeras and 65% for the 
complete donor chimeras. We conclude that in this study, mixed 
chimerism Is not associated with a higher Incidence of relapse. 
In chapter 5 we analyse the origin of red cells (using red cell 
phenotyping), Τ lymphocytes (using both cytogenetic analysis and 
RFLPs studies), and of granulocytes and bone marrow cells (using 
RFLPs studies) in 10 consecutive patients. All received bone 
marrow grafts depleted of lymphocytes us ing counterflow 
centrifugatlon. Analyses were performed on identically timed 
samples from 6 m o n t h s after t ransplantat ion onward. After 
correction for the higher sensitivity of red cell phenotyping, results 
of red cell phenotyping were concordant with RFLPs studies of 
granulocytes and bone marrow cells In all cases studied. Outcome of 
cytogenetic analysis and RFLPs studies of Τ lymphocytes were 
concordant in all 10 cases. Two patients had only mixed chimerism 
In Τ lymphocytes but not in red cells nor in granulocytes. In one of 
these two patients the absence of mixed chimerism was confirmed 
with RFLPs studies of bone marrow cells, cytogenetic analysis of 
bone marrow cells of the second patient showed only metaphases 
of donor-type. These data show t h a t red cell phenotyping 
represented the hematopoietic chimeric state of granulocytes and 
nucleated bone marrow cells. Cytogenetic analysis or RFLPs studies 
of Τ lymphocytes have increased the number of Instances of mixed 
chimerism, b u t this reflects the higher incidence of mixed 
chimerism in the clonogenic Τ cell population. These cells are less 
sensitive to radiochemotherapy than the hematopoietic stem cells 
and have retained the capacity for (limited) selfrenewal. 
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In chapter 6 we describe chromosome studies on 121 paired 
samples of phytohemagglutinln-stimulated blood and unstimulated 
bone marrow cells of 57 recipients of a graft which was lymphocyte 
depleted using counterflow centrifugation. The paired samples 
were taken simultaneously 6 to 108 months after transplantation. 
The incidence of mixed chimerism was significantly higher in 
blood than in bone marrow cells. The higher number of mixed 
lymphoid chimeras is caused by autologous Τ lymphocytes which 
have survived conditioning regimen and/or by donor Τ lymphocytes 
which persisted after disappearance of the marrow graft. 
The autologous blood and bone marrow metaphases of the mixed 
chimeras of the patients in remission showed multiple non-clonal 
abnormalities probably as a consequence of radiation damage. In 
almost all patients with relapsed CML the P h 1 chromosome 
together with multiple non-clonal and clonal chromosomal 
abnormalities were observed. 
Chimerism had no significant Impact on the Incidence of chronic 
GVHD but the overall incidence of chronic GVHD was too low to 
allow an accurate assessment. 
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SAMENVATTING 
In hoofdstuk 1 definiëren we de term chimerisme. Iemand die met 
succes getransplanteerd is met beenmerg van een donor bezit in 
principe cellen van twee verschillende individuen. Naast zijn eigen 
lichaamscellen heeft hij beenmerg-en bloedcellen van de donor: hij 
is een chimeer. Ondanks het feit dat de term chimerisme in 
principe betrekking heeft op een individu en niet op een 
orgaanweefsel, wordt het begrip chimerisme nader gedefinieerd 
naar de oorsprong van de beenmerg- en bloedcellen. Zijn na een 
beenmergtransplantatie alle bloed- en beenmergcellen afkomstig 
van de donor, dan is de chimeer compleet en heeft de 
getransplanteerde een complete donor chimeer. Indien één of 
meer cellijnen in het bloed en/of het beenmerg afkomstig zijn van 
de beenmergdonor en één of meer cellijnen in het bloed en/of het 
beenmerg afkomstig zijn van de getransplanteerde, dan is de 
chimeer gemengd (mixed) en heeft de patiënt een gemengde 
chimeer. De benaming chimeer (chimera) is ontleend aan een 
monsterdier (de "Chimera") uit de griekse mythologie. Het lichaam 
van dit monster was van voren een leeuw, in het midden een geit 
(het griekse woord chimera betekent geit) en van achteren een 
draak. 
In hoofdstuk 2 worden de ontwikkelingen beschreven die 
u i te inde l i jk geleid h e b b e n to t de mogel i jkheid om 
beenmergtransplantaties te verrichten met behulp van beenmerg 
van donors. In de Jaren vijftig werd aangetoond dat dieren 
b e s c h e r m d k o n d e n worden tegen de gevolgen van 
beenmergvernietigende bestraling door de milt t i jdens de 
bestriding met lood af te dekken of door infusie van beenmerg van 
een donor. Aanvankelijk werd het beschermend effect aan een 
humorale factor toegeschreven doch later werd duidelijk dat het 
beenmerg van de donor uitgroeide ín de beenmergholte van de 
ontvanger. De resu l ta ten van beenmerg t ransp lan ta t i e bij 
proefdieren en mensen met leukemie waren echter teleurstellend. 
Ontvangers van genetisch identiek beenmerg overleden met een 
recidief van de leukemie, zij die niet genetisch identiek beenmerg 
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kregen overleden meestal aan de gevolgen van de "secundaire 
ziekte", later herkend als de omgekeerde afstotingsreactie of graft-
versus-host disease (GVHD). BIJ proefdieren en patiënten die langer 
overleefden doch uiteindelijk overleden met GVHD kon meestal 
geen leukemie meer aangetoond worden. Blijkbaar ging GVHD 
gepaard met een anti-leukemisch effect. De kans op GVHD is 
kleiner naarmate het weefseltype van patiënt en donor méér 
overeenstemmen. Het weefseltype wordt genetisch bepaald en 
selectie van beenmergdonors op basis van het weefseltype leverde 
een grote bijdrage aan de preventie van GVHD en zodoende aan het 
uiteindelijke slagen van beenmergtransplantaties. Toch bleef GVHD 
veel morbiditeit en mortaliteit veroorzaken. Verwijdering van de Τ 
lymfocyten uit het donor beenmerg veroorzaakte een sterke daling 
in zowel de incidentje als de ernst van GVHD maar ging gepaard 
met een toename van het aantal recldieven. Bij deze patiënten kan 
de kans op recidlef verminderd worden door intensivering van de 
conditionering. 
Allogene beenmergtransplantatie is een, niet meer experimen-
tele, behandeling voor een steeds groter aantal maligne en niet 
maligne ziekten. Door het oprichten van nationale en internationale 
bestanden van beenmergdonors kunnen steeds meer patiënten 
genezen worden met behulp van een allogene beenmergtrans-
plantatie. 
In hoofdstuk 3 worden de resultaten beschreven van de eerste 80 
patiënten die een allogene beenmergtransplantatie ondergingen in 
het Academisch Ziekenhuis te Nijmegen. Transplantatie werd 
verricht wegens acute leukemie of chronische myeloide leukemie 
(CML). De beenmergdonors waren genotypisch identieke broers of 
zusters . Alle patiënten kregen beenmerg waaruit 98% van de 
lymfocyten verwijderd was door middel van tegenstroom-
centrifugatie (counterflow centrifugation). De mediane leeftijd van 
de pat iënten was 31 Jaar. Conditionering geschiedde met 
cyclofosfamide en gefractioneerde totale l ichaamsbestral ing. 
Bovendien kregen 43 pa t iën ten cytos lne-arabinoslde of 
anthracyclines toegediend. Het beenmerg sloeg niet aan of werd 
afgestoten bij 4 van de 77 patiënten (5%) die voor evaluatie in 
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aanmerking kwamen. De kans op acute GVHD graad II of hoger en 
ernstige chronische GVHD was laag en bedroeg respectievelijk 15% 
en 12%. De recidiefkans geprojecteerd op 3 Jaar na transplantatie 
bedroeg respectievelijk 30%, 3 5 % en 38% voor pat iënten 
getransplanteerd voor acute myeloide leukemie (AML) in eerste 
complete remissie (CRI), acute lymfatische leukemie (ALL) in CRI 
en CML in eerste chronische fase (CP1). De kans op overleving 
zonder leukemie geprojecteerd op 3 Jaar na transplantatie bedroeg 
respectievelijk 56%, 42% en 49% voor patiënten getransplanteerd 
voor AML-CRl, ALL-CRl en CML-CP1. In tegenstelling tot paüënten 
getransplanteerd voor CML-CP1 was de recidiefkans en de kans op 
overleven zonder leukemie voor patiënten die getransplanteerd 
werden voor AML-CRl en ALL-CRl viergelljkbaar met de resultaten 
uit de l i teratuur betreffende beenmergtransplantaties met niet 
gedepleteerd beenmerg. Voor de in Nijmegen getransplanteerde 
80 patiënten hadden de verschillende conditioneringsschema's 
geen invloed op de kans op acute GVHD graad II of hoger, noch op 
de kans op ernstige chronische GVHD, noch op de recidiefkans en 
evenmin op de kans op overleving noch de kans op leukemie-vrije 
overleving. Gewezen werd op het grote aantal gemengde chimeren. 
Geconcludeerd wordt dat tegenstroom centrifugatle de inciden-
tie en de ernst van acute en chronische GVHD vermindert en dat 
de kans op overleven en op overleven zonder leukemie voor 
patiënten die getransplanteerd werden voor leukemie in CRI en 
CP1 kan wedijveren met de resultaten zoals beschreven in de 
l i t e ra tuur die bet rekking hebben op pat iënten die niet 
gedepleteerd beenmerg ontvingen. 
In hoofdstuk 4 vermelden wij het grote aantal patiënten met 
gemengd chimerisme na transplantatie met beenmerg waaruit de 
lymfocyten verwijderd werden met behulp van tegenstroom 
centrifugatle. De beenmergdonors waren genotypisch identieke 
broers en zusters. Gemengd chimerisme werd aangetoond met 
behulp van fenotypering van bloedgroepen, cytogenetisch 
onderzoek van perifere lymfocyten en beenmergcellen en middels 
onderzoek van perifere bloedcellen met behulp van restrictie-
fragmentlengte polymorfisme (RFLP). Zes maanden n a de 
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beenmergtransplantatie bleken 32 van de 48 getransplanteerden 
(67%) gemengde chlmeren te hebben. Blijkbaar werd het grote 
aantal gemengde chimeren veroorzaakt door Τ cel depletle van het 
beenmerg en de grote gevoeligheid van de door ons gebruikte 
fenotypering van erythrocyten. De gevoeligheid van deze methode is 
0,01%, dit wil zeggen dat één positieve cel aangetoond kan worden 
te midden van 9999 negatieve cellen). De recidief-vrije overleving 
gerekend vanaf 6 maanden tot 4 Jaar na transplantatie was 85% 
voor de patiënten met gemende chimeren en 65% voor de 
patiënten die uitsluitend donor cellen hadden. 
De conclusie van deze studie is dat gemengd chimerisme niet 
geassocieerd is met een verhoogde kans op recidief. 
In hoofdstuk 5 wordt de origine geanalyseerd van rode bloedcellen 
met behulp van fenotypering van bloedgroepen en van Τ lympho-
cyten middels cytogenetisch onderzoek en RFLP. De oorsprong van 
granulocyten en beenmergcellen werd bepaald door middel van 
RFLP. Dit geschiedde bij 10 patiënten die beenmerg ontvingen 
waaruit 98% van de lymfocyten verwijderd was met behulp van 
tegenstroom-centrifugatie. De verschil lende methoden van 
onderzoek werden toegepast op bloed- en beenmergmonsters die 
gerekend vanaf 6 maanden na transplantatie simultaan afgenomen 
werden. Na correctie voor de grotere gevoeligheid van bloedgroep-
fenotypering vonden we een volledige overeenkomst tussen de 
resultaten van fenotypering van rode bloedcellen en van RFLP van 
granulocyten en beenmergcellen. De resultaten van onderzoek van 
Τ lymfocyten met behulp van cytogenetlca en RFLP stemden 
volledig overeen. Twee patiënten hadden uitsluitend gemengde 
chimeren in hun Τ lymfocjrten maar niet in hun rode bloedcellen of 
granulocyten. Eén van deze twee patiënten had met RFLP ook geen 
gemengd chimerisme in de beenmergcellen. Cytogenetisch onder-
zoek van beenmergcellen van de tweede patiënt liet uitsluitend 
cellen van donor origine zien. Fenotypering van erythrocyten was 
voor deze 10 patiënten representief voor het chimerisme van 
granulocyten en kernhoudende beenmergcellen. Door onderzoek 
van het chimerisme van Τ lymfocyten met behulp van cytogenetlca 
en RFLP neemt het aantal patiënten met gemengde chimeren toe 
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maar dit weerspiegelt het grotere aantal gemengde chimeren in de 
donogene Τ cel populatie. Deze cellen zijn minder gevoelig voor 
radio-chemotherapie dan de hematopoietische s tam cel en 
behouden hun vermogen tot (beperkte) proliferatie. 
In het laatste hoofdstuk, hoofdstuk 6, worden de resul taten 
beschreven van het cytogenetisch onderzoek van 121 gepaarde, 
door fytohemagglutinine gestimuleerde bloedcellen en niet 
gestimuleerde beenmergcellen. Deze bloed- en beenmergmonsters 
waren afkomstig van 57 patiënten die getransplanteerd werden 
met beenmerg waaruit 98% van de lymfocyten verwijderd was door 
middel van tegenstroom centrifugatie. De gepaarde monsters 
werden tussen 6 en 108 maanden na de beenmergtransplantatie 
afgenomen. De incidentie van gemengde chimeren was significant 
hoger in bloed- dan in beenmergcellen. Méér gemengde chimeren 
werden aangetoond in bloed- dan in beenmergcellen. Het groter 
aantal gemengde chimeren in bloedcellen werd veroorzaakt door 
zowel Τ lymphocyten van patiënt-origine die de conditionering 
voorafgaand aan de beenmergtransplantatie overleefd hadden als 
door Τ lymfocyten van de donor die bleven circuleren n a 
verdwijning van het transplantaat door afstoting of recidief. 
De bloed- en beenmergcellen van patiënt origine in de gemengde 
chimeren van patiënten in remissie vertoonden multipele niet-
clonale afwijkingen die het gevolg waren van de bestraling 
voorafgaande aan de transplantatie. Bijna alle patiënten met een 
recidief chronische myeloide leukemie na de beenmergtrans-
plantatie, hadden naas t het Philadelphia chromosoom multipele 
niet-clonale en clonale chromosomale afwijkingen. Het soort 
chimerisme (gemengd of compleet) had geen significante invloed 
op de incidentie van chronische omgekeerde afstotingsreactie 
waarbij opgemerkt dient te worden dat de incidentie van 
chronische omgekeerde afstotingsreactie in de onderzochte 
populatie laag was. 
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